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About the Canadian Research Initiative in Substance Misuse 
Funded by the Canadian Institutes of Health Research (CIHR), the Canadian Research Initiative in 
Substance Misuse (CRISM) is a national research-practice-policy network focused on substance 
use disorders, comprising four large interdisciplinary regional teams (Nodes) representing British 
Columbia, the Prairie Provinces, Ontario, and Quebec/Atlantic. Each CRISM node includes regional 
research scientists, service providers, policy makers, community leaders, and people with lived 
experience of substance use disorders. CRISM’s mission is to translate the best scientific evidence 
into clinical practice, health services, and policy change. More information about CRISM can be 
found at: https://crism.ca.
About this Document
This document is one of a series of six national guidance documents, rapidly developed by the 
CRISM network at the request of the Government of Canada. Collectively, the six documents address 
urgent needs of people who use substances, service providers, and decision makers in relation to the 
COVID-19 pandemic. The urgent nature of this work required rapid development and dissemination 
of this guidance. This, and the continuing evolution of the knowledge base regarding COVID-19, 
precluded CRISM from conducting a comprehensive review of the relevant literature. However, when 
available, scientific evidence is cited in support of the expert advice offered herein.
The guidance provided in this document is subject to change as new information becomes available. 
Readers should note that the intent of this document is to provide general guidance rather than 
detailed procedural and logistical advice. Readers are advised to consult local public health and medical 
authorities for specific input on navigating their own unique regulatory and policy environments, as 
necessary.
The CRISM/COVID-19 guidance documents cover the following topics:
• Supporting People Who Use Substances in Shelter Settings During the COVID-19 Pandemic (this 
document)
• Telemedicine Support for Addiction Services
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• Harm Reduction Worker Safety
• Recovery Environments
• Supporting People Who Use Substance in Acute Care Settings
• Strategies to Help Individuals Self-Isolate for People who use Drugs
Each document was developed by a core CRISM regional authorship committee, drawing on expert 
knowledge, available scientific evidence, and a review of relevant documentation from public health 
authorities. Draft documents produced by each authorship committee were reviewed by pan-Canadian 
panels of content and clinical experts.  People with lived and living experience of substance use have 
participated in the production of the CRISM/COVID-19 guidance document series, either as part of 
review or authorship committees.  A Canadian Institutes of Health Research (CIHR) Directed Operating 
Grant to CRISM provided funding for this work.
Disclaimer for Health Care Providers 
The recommendations in this guidance document represent the view of the National Operational 
Guidance Document Review Committee, arrived at after careful consideration of the available 
scientific evidence and external expert peer review. The application of the guidance contained in 
this document does not override the responsibility of health care professionals to make decisions 
appropriate to the needs, preferences, and values of an individual patient, in consultation with 
that patient (and their guardian[s] or family members, when appropriate), and, when appropriate, 
external experts (e.g., specialty consultation). When exercising clinical judgment in supervising drug 
consumption and caring for patients, health care professionals are expected to take this guidance 
document fully into account while upholding their duties to adhere to the fundamental principles and 
values of their relevant codes of ethics. Nothing in this guidance document should be interpreted in a 
way that would be inconsistent with compliance with those duties.
Legal Disclaimer 
While the individuals and groups involved in the production of this document have made every effort 
to ensure the accuracy of the information contained in this guidance document, please note that the 
information is provided “as is” and that CIHR and CRISM make no representation or warranty of any 
kind, either expressed or implied, as to the accuracy of the information or the fitness of the information 
for any particular use. To the fullest extent possible under applicable law, CIHR and CRISM disclaim 
and will not be bound by any express, implied, or statutory representation or warranty (including, 
without limitation, representations or warranties of title or non-infringement). This document is 
intended to provide guidance to build a supervised consumption service and facilitate substance use 
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care. This guidance document is not intended as a substitute for the advice or professional judgment 
of a health professional, nor is it intended to be the only approach to the management of a clinical 
problem. We cannot respond to patients or patient advocates requesting advice on issues related to 
medical conditions. If you need medical advice, please contact a local health care professional.
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Detailed Summary – Disclosure of Interests (DOI) for CRISM 
Rapid Response COVID‑19 Shelter Guidance Document
In accordance with the Guidelines International Network’s Principles for Disclosure of Interests and 
Management of Conflicts (1), authorship committee members and external reviewers were asked to 
disclose all sources and amounts of direct and indirect (i.e., research support) remuneration from 
industry, for-profit enterprises, and other entities that could potentially introduce real or perceived 
risk of bias. In addition, authorship committee members and external reviewers were asked to report 
indirect sources of bias, such as academic advancement, clinical revenue, and professional or public 
standing that could potentially influence interpretation of research evidence and formulation of 
recommendations.
1.   Schünemann HJ, Al-Ansary LA, Forland F, et al. Guidelines international network: principles for disclosure of interests and management of 
conflicts in guidelines. Ann Intern Med. 2015;163(7):548-553.
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Of 27 authorship committee members and external reviewers, 14 acknowledged potential direct 
conflicts of interest. Of the 14, only one (an external reviewer) provided paid consultation to private 
companies including Merck, Abbott, ViiV, Rickett-Benkiser, Gilead, BMS and Indivior. There were no 
authorship committee members or external reviewers with commercial interests. On review, potential 
conflicts of interest were not deemed to be of sufficient weight or relevance to warrant exclusion 
from the guidance committee.
Most (22, 81%) authorship committee members and external reviewers disclosed potential indirect 
sources of bias (e.g., specialization in addiction medicine, advisory board and committee membership, 
involvement with SCS programs, provincial substance use treatment programs, previous guideline 
development, research interests).  Of these, 11 acknowledged that they have publicly stated support 
for SCS. In order to mitigate the risk of bias while maximizing the contributions of members in 
their respective areas of expertise, authorship committee members and external reviewers were 
reminded to consider any influential factors or sources of bias during the review process. Authors 
and reviewers contributed to review of sections related to their areas of expertise as well as the 
overarching guideline content to ensure that a broad range of clinical and academic specializations 
was adequately represented.
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ABBREVIATIONS
AED: Automated External Defibrillator
AGMP: Aerosol Generating Medical Procedure
AIDS: Acquired Immunodeficiency Syndrome
CBT: Cognitive-Behavioral Therapy
CIHR: Canadian Institutes of Health Research
COVID‑19: Novel Coronavirus disease of 2019
CPR: Cardiopulmonary Resuscitation
CRISM: Canadian Research Institute in Substance Misuse 
EMS: Emergency Medical Service 
HCV: Hepatitis C Virus
HIV: Human Immunodeficiency Virus
iOAT: Injectable Opioid Agonist Treatment 
MAP: Managed Alcohol Programs 
MET: Motivational Enhancement Therapy
NRT: Nicotine Replacement Therapy 
OAT: Opioid Agonist Treatment 
OPS: Overdose Prevention Sites
PPE: Personal Protective Equipment 
PWLE: People With Lived and Living Experience
SCS: Supervised Consumption Services 
SROM: Slow Release Oral Morphine 
UPHNS: Urgent Public Health Need Site  
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1.0  Key points of the guidance 
document
• The COVID‑19 pandemic has compounded risks already posed by the overdose epidemic, 
and placed people who use substances and are experiencing homelessness or housing 
vulnerability at high risk of negative health outcomes including death.
• The purpose of this guidance document is to support organizations operating new or existing 
shelter settings to provide evidence‑informed care for people who use substances during 
the COVID‑19 pandemic in Canada.
• For shelters providing care to people who use substances during COVID‑19, a pragmatic 
approach assumes that some level of drug and alcohol use will continue irrespective of 
formal or informal bans or criminal prohibitions.
• Under a harm reduction approach, modifying risks associated with unsafe substance use 
practices or settings takes precedence over enforcing abstinence, and residents are supported 
to access care based on self‑determined needs and goals.
• Design and delivery of shelter services should incorporate perspectives of people with lived 
or living experience of substance use and homelessness or housing vulnerability.
• Integrating supervised illegal drug consumption services into shelter settings is feasible, and 
has the potential to reduce overdose‑related mortality and other negative health outcomes.
• A variety of supervised consumption service models can be operated during COVID‑19 
through use of appropriate infection prevention and control measures and personal 
protective equipment.  
• Supervised consumption services should regularly review infection prevention and control 
and personal protective equipment procedures to ensure they remain consistent with the 
latest public health guidance in their jurisdiction.
• Shelters should facilitate access to healthcare providers who are able to assist with substance 
use disorder treatment, withdrawal management, and substance use stabilization/risk 
mitigation.
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• A variety of first‑ and second‑line substance use disorder treatments are available to support 
shelter residents who wish to abstain from drugs and/or alcohol.
• Not all residents will accept or stabilize on evidence‑based treatment options for their 
substance use disorders. In these cases, health care professionals should consider providing 
access to replacement medications for withdrawal and craving management, and to mitigate 
harms associated with ongoing procurement and use of substances from the illegal drug 
market.
• Managed alcohol programs (MAPs) are a promising option for supporting shelter residents 
whose pattern of alcohol consumption may place them at increased risk of harm during 
COVID‑19.
• There are multiple possible avenues for shelter residents to receive their prescribed 
medications, including multi‑day dispensing, pharmacy delivery, and on‑site pharmacy 
services.
• Psychosocial interventions and supports should be routinely offered alone or in conjunction 
with prescribed medications or managed alcohol.
• Any resident receiving substance use disorder treatment, replacement pharmacotherapy, 
and/or managed alcohol should be assisted in achieving continuity of care following 
discharge from the shelter.
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2.0  Purpose and Scope
On March 11, 2020 the World Health Organization declared COVID-19, caused by a novel coronavirus, 
a pandemic, citing concern over alarming levels of spread and severity across the globe. People who 
are experiencing homelessness or housing vulnerability are particularly at risk of COVID-19 (1). In 
Canada, homelessness is defined as “the living situation of an individual or family who does not have 
stable, permanent, appropriate housing, or the immediate prospect, means and ability of acquiring 
it” (2), and incorporates people who do not have housing and those living in inadequate conditions. 
People experiencing homelessness often live in dense and overcrowded conditions and do not have 
access to the resources required to take protective measures against the virus, such as space to 
practice physical distancing and access to hygiene amenities, increasing their risk of infection (3). In 
addition to lacking housing that would facilitate adhering to infection prevention guidelines, people 
who are experiencing homelessness or housing vulnerability are also more likely to congregate with 
others to access essential services (e.g., drop-in services, government resources, pharmacies), use 
public transit, regularly travel long distances, and be subject to law enforcement and incarceration, 
further increasing their risk of exposure to COVID-19. 
We know that lack of safe, stable housing increases the risk of a host of negative health outcomes, 
and COVID-19 is no exception. Populations experiencing homelessness or housing vulnerability 
have a higher prevalence of chronic disease and other comorbidities (e.g., respiratory problems and 
health conditions that compromise immunity) compared to the general population, making them 
more susceptible to severe outcomes associated with COVID-19 infection (4). Many jurisdictions are 
attempting to rapidly shelter people who are experiencing homelessness or housing vulnerability 
as part of a broader pandemic response, either by implementing new, or reconfiguring existing, 
shelter settings. These efforts should prioritize the health, safety, and human rights of people who are 
experiencing homelessness or housing vulnerability and support them in addressing their pre-existing 
health conditions when possible. 
People who use substances and are experiencing homelessness or housing vulnerability represent a 
particularly at-risk subpopulation. Those reliant on a highly toxic illegal drug market are at high risk of 
overdose morbidity and mortality and other negative health outcomes (e.g., cellulitis, endocarditis, 
human immunodeficiency virus [HIV], hepatitis C virus [HCV]). Travel restrictions and border closures 
related to COVID-19 are causing new disruptions in the illegal drug supply (5). The health consequences 
of such disruptions are not fully known, but there is potential for increased risk of withdrawal or 
related complications (5). It is also possible that supply disruptions could lead to consumption of more 
dangerous substances or transition to riskier, but more efficient, routes of administration. A number 
of Canadian jurisdictions have reported spikes in overdose during COVID-19, however the extent to 
which these trends reflect changes to the illegal drug supply, versus the impacts of physical distancing, 
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isolation, stress and anxiety, or other underlying factors is not currently known (6–10). Disruptions in 
alcohol access for people with high risk drinking patterns and alcohol use disorders may also lead to 
serious medical complications, including alcohol withdrawal syndrome, seizures, and increased risk 
of significant harm or death. 
The purpose of this guidance document is to support organizations operating new or existing shelter 
settings in providing evidence-informed care for people who use substances during the COVID-19 
pandemic in Canada. Strategies discussed herein are intended to mitigate risks of overdose death, 
withdrawal, transmission of bloodborne infections, and other poor health outcomes while also 
supporting people to adhere to physical distancing and self-isolation requirements for preventing 
COVID-19 transmission. We define shelter settings to include existing day and overnight homeless 
shelters, as well as new temporary shelters implemented to support people experiencing homelessness 
or housing vulnerability during the COVID-19 pandemic. This document is thus intended to be relevant 
for shelters offering both congregate or separate accommodations for residents (e.g. hotel rooms, 
semi-private rooms) and incorporating varying degrees of medical support.
The guidance herein addresses the needs of two distinct subpopulations of people staying in shelters: 
[1] those accessing services who are asymptomatic, not under any public health directive to self-isolate 
and not undergoing any investigations related to COVID-19; and [2] those who are self-isolating after 
testing positive for COVID-19, having high-risk exposure to a contact with known COVID-19 infection, 
or are otherwise under a related investigation. Specifically, this document provides:
• An overview of the rationale for the need to support people who use substances and are 
experiencing homelessness or housing vulnerability during COVID-19. 
• Guidance on how to obtain a legal exemption, implement, and operate a temporary supervised 
consumption service [also referred to as an Urgent Public Health Need Site (11)].
• Guidance on providing or facilitating access to a range of conventional first- and second-line 
substance use disorder treatments and recovery options.
• Guidance on risk mitigation strategies, such as replacement pharmacotherapy or managed 
alcohol programs, to support people with substance use disorders in emergency shelter 
settings when conventional treatments are not effective or appropriate. 
• Advice for monitoring and evaluating the provision of these services.
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Readers should note that this document does not address the provision of harm reduction supplies 
outside the context of a supervised consumption service. For more information on best practices for 
supply distribution, please see:
• Best Practice Recommendations for Canadian Harm Reduction Programs that Provide Services 
to People who use Drugs and are at Risk for HIV, HCV, and Other Harms: Part 1; Working Group 
on Best Practice for Harm Reduction Programs in Canada (12).
• Best Practice Recommendations 2 for Canadian Harm Reduction Programs that Provide Service 
to People who use Drugs and are at Risk for HIV, HCV, and Other Harms; Working Group on 
Best Practice for Harm Reduction Programs in Canada (13).
2.1  DEVELOPMENT 
This rapid guidance on supporting people who use substances in shelter settings was developed 
to provide urgent advice in the context of the COVID-19 pandemic. Members of the authorship 
committee developed this document based on expert knowledge, scientific evidence, and a review of 
documentation from public health authorities and other relevant organizations. 
The urgent nature of this work required rapid development and dissemination of this guidance. 
This timeline and the continuing evolution of the knowledge base regarding COVID-19 precluded a 
comprehensive review of the relevant literature. However, where available, academic research is cited 
in support of the expert advice offered herein. The guidance provided in this document is subject to 
change as new information becomes available. 
Readers should note that the intent of this document is to provide general guidance for supporting 
people who use substances in shelter settings across Canada rather than detailed procedural 
instructions for implementing supervised consumption services or prescribing pharmacotherapy. 
Implementation processes and regulations may vary by local, regional, or provincial/territorial 
jurisdiction. Readers should consult local public health and medical authorities for advice on navigating 
their own unique regulatory and policy environments, as necessary. 
Note that a number of external organizations have produced relevant resources for supporting people 
who use substances in shelter settings. Where possible, we have linked to external documents or 
websites which may be useful for readers of this guidance; at the time of publication, all links were 
confirmed to be active.
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2.2  INTENDED AUDIENCE
The target audience for this rapid guidance document includes both clinical and non-clinical staff 
organizing and delivering care to people accessing day, overnight, and/or medical isolation shelters 
during the COVID-19 pandemic. The guidance contained in this document may also be relevant for 
policymakers, public health authorities, groups representing people who use drugs and those in 
recovery, advocates, and other people working to prevent the spread of COVID-19, and protect the 
health and wellbeing of people who are experiencing homelessness or housing vulnerability.
2.3  GUIDING PRINCIPLES
This document is guided by the principles of harm reduction and engaging people with lived or living 
experience in the development and operation of services designed for people who use substances 
and are experiencing homelessness or housing vulnerability.
Harm reduction is an umbrella term for various policies and practices that aim to reduce harms 
associated with consuming substances without requiring a reduction in or abstinence from substance 
use. Substance use can occur along a continuum from beneficial to harmful, and people deserve 
non-judgmental care that supports their autonomy and dignity regardless of where they fall on that 
continuum. Under a harm reduction approach, modifying risks associated with unsafe drug use 
practices or settings takes precedence over enforcing abstinence (14,15), and people are supported 
to access health and social services (e.g. medical care, substance use treatment, counselling, housing, 
income support) based on self-determined needs and goals. Shelters or any organization adopting the 
interventions outlined in this document should endorse clear and well communicated harm reduction 
policies that embrace core international principles (16,17). Harm reduction training and education 
should be available to all staff and include a review of related principles and values, and opportunities 
to reflect on the broader social, legal, and policy context of substance use. If hiring new staff, look for 
applicants with values that align with harm reduction philosophy. This is essential to create a culture 
of harm reduction (18,19).
Engaging people with lived or living experience of substance use and homelessness or housing 
vulnerability in the design and delivery of services is essential to ensure that the services achieve 
their intended outcomes and meet the needs of their target population. While meaningfully engaging 
people with lived or living experience may be challenging in the context of the pandemic, operators 
should attempt to abide by the principle of ‘nothing about us without us’ as much as possible. Regional 
or national groups advocating for people who use substances can often facilitate contact with local 
people who use substances. When consulting or employing people with lived or living experience, it 
is important to ensure equitable compensation for expertise and labour (20). The following resources 
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provide more guidance on engaging people with lived or living experience:
• Having a Voice and Saving Lives; CRISM People with Lived Expertise of Drug Use (PWLE) 
National Working Group (21)
• Engaging People who use Drugs in Policy and Program Development: A Review of the Literature; 
Substance Abuse Treatment, Prevention, and Policy (22)
• “Nothing About Us Without Us” Greater, Meaningful Involvement of People Who Use Illegal 
Drugs: A Public Health, Ethical, and Human Rights Imperative; Canadian HIV/AIDS Legal 
Network (23)
• Peer Worker Involvement in Low-Threshold Supervised Consumption Facilities in the Context 
of an Overdose Epidemic in Vancouver, Canada; Social Science & Medicine (24)
• Peerology; Canadian AIDS Society (20)
2.4  BACKGROUND 
Canada has a growing homelessness crisis. An estimated 35,000 people experienced homelessness 
each night in 2016 (25), and this number has likely increased since. People experiencing homelessness 
have a high prevalence of substance use disorders, but to date there have been only relatively 
small Canadian studies on the topic. Based on these, up to 82% of people who were experiencing 
homelessness qualified for a diagnosis of substance use disorder (26), defined as either drug use 
or alcohol use disorders. Other studies found lower prevalence, but in all studies, prevalence was 
multifold to that found in the general population (27,28). Amidst rising homelessness, Canada is also 
experiencing an overdose crisis. 
Canada has seen an increase in overdose deaths since the 1990s (29), and the widespread 
contamination of the illegal drug supply has further intensified the crisis (30). The opioid-related 
overdose death rate reached 12.4 per 100,000 in 2018 (31,32). The most up-to-date national data 
suggests that the prevalence rate decreased to 10.3 per 100,000 in the first 9 months of 2019 (32). 
However, recent reports from a number of Canadian jurisdictions suggest that overdose deaths may 
be increasing during the pandemic (6–10). The ongoing overdose epidemic requires comprehensive 
public health and addiction treatment responses. 
The outbreak of COVID-19 was declared a global pandemic by the World Health Organization on 
March 11, 2020 (33). The most common symptoms of this viral infection include fever and cough (34). 
In more severe cases, sepsis, respiratory failure, and heart failure can occur (34). COVID-19 is believed 
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to spread mainly through respiratory droplets from coughing or sneezing, prolonged personal contact, 
or contact with contaminated surfaces (35,36). Globally, there have been over 4 million confirmed 
cases and over 295,000 deaths (37), although this is likely underestimated. In Canada, as of May 13, 
2020, there have been 72,278 confirmed cases and 5,304 deaths (38).
The COVID-19 pandemic has compounded risks already posed by the overdose epidemic, and these 
intersecting public health emergencies place people who use substances and are experiencing 
homelessness or housing vulnerability at extreme risk of negative outcomes. Physical distancing and 
self-isolation protocols further exacerbate the risk of overdose death, as these protocols may lead 
more people to use substances alone, limiting the presence of bystanders who could intervene in 
the event of an overdose. If an overdose occurs in public, intervening bystanders may inadvertently 
expose themselves or the person who has overdosed to COVID-19 when providing CPR or other 
interventions, if not equipped with appropriate PPE. In shelter settings where PPE may be in short 
supply, staff are less able to respond effectively without risking potential COVID-19 exposure or 
transmission. Alternatively, lifesaving interventions such as rescue breathing and/or CPR may be 
delayed until EMS arrives, increasing the risk of anoxia and brain damage. These situations may lead 
to adverse outcomes for the person experiencing an overdose, including death, and significant moral 
distress for staff. 
The COVID-19 pandemic may intensify existing barriers to health care (39–42) and harm reduction 
services. Comorbid health conditions commonly experienced by people with substance use disorders 
(43–45) may also place them at an elevated risk for severe COVID-19-related complications and 
mortality (46). COVID-19 has also disrupted ‘open air’ drug markets due to public health orders 
forbidding public congregating. As a result, those reliant on these markets may need to travel 
longer distances to obtain substances potentially from unfamiliar sellers, and consume drugs in new 
surroundings, which could exacerbate risk of COVID-19 infection or transmission, overdose, arrest 
and incarceration, and violent victimization. Finally, people who are experiencing homelessness or 
housing vulnerability may lack basic resources to protect themselves from COVID-19 by adhering to 
physical distancing, self-isolation, and hygiene guidelines, further increasing risk of infection (35).
Shelter settings in Canada have adapted their service models in response to the pandemic. Many 
existing emergency shelters that house people overnight or provide daytime drop-in spaces are 
reducing the number of people allowed in at one time and/or modifying their spaces to try to align 
with physical distancing guidelines. These services may also be altering their hours or temporarily 
relocating to larger facilities in an attempt to reduce COVID-19 transmission risks. Many jurisdictions 
are also establishing medical isolation shelters, within existing or in new settings (e.g. convention 
centres or other large facilities), to support people who are experiencing homelessness or housing 
vulnerability to self-isolate if they have had a known high-risk exposure, are under COVID-19 
investigation, or test positive for the virus. A number of jurisdictions are also supporting people to 
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either physically distance or isolate using hotels or similar kinds of temporary accommodations with 
integrated support services. 
Although shelters are implementing various measures to reduce the risk of COVID-19, many continue 
to face challenges containing infection (47,48). Early studies from the United States have found case 
rates of 15-66% in some shelter settings (49–52). The COVID-19 pandemic dramatically illustrates 
a public health and human rights imperative to provide housing for all. Safe and stable housing is 
the first-line defense against COVID-19 (53,54). While shelters can help respond to the immediate 
need to mitigate public health risks of COVID-19, they are only a temporary and inadequate solution 
to pre-existing structures of marginalization and exclusion (55) and ultimately do not advance the 
human right to housing (54,56). While shelters may be acceptable interim measures, they should not 
replace work to ensure safe and adequate housing for all.
For shelters providing care to people who use substances during COVID-19, a pragmatic approach 
assumes that some level of drug and alcohol use will continue irrespective of formal or informal bans 
or criminal prohibitions (57,58). This means that people who use substances should not be excluded 
from shelter settings because of substance use policies that prohibit use on site or possession of 
alcohol or drugs. Beyond addiction, people use drugs for a variety of reasons including for stimulation, 
to reduce stress and anxiety, to manage pain and mental health conditions, and for pleasure (59–61). 
To reduce risk of substance-related harms and promote safety of both residents and staff, shelters 
should integrate harm reduction approaches and interventions into their service models. 
Operators providing temporary housing or shelter during the COVID-19 pandemic should consider 
adding or bolstering strategies for accommodating active drug and alcohol use, and make concerted 
efforts to support people who use substances to stay as safe and healthy as possible. Promising 
strategies for achieving this are: [1] integration of supervised illegal drug consumption services 
into shelters, and [2] provision of substance use disorder treatment and related recovery supports, 
managed alcohol programs, and replacement pharmacotherapy to support those who use substances 
to mitigate their risk of COVID-19 transmission, overdose, and withdrawal. A recent systematic review 
of reviews illustrates the utility of these approaches (62). It found that supervised consumption services 
and pharmaceutical interventions (e.g., buprenorphine, methadone, and injectable diacetylmorphine 
or hydromorphone) reduced mortality and morbidity, and improved other outcomes amongst people 
experiencing homelessness, and that managed alcohol programs helped reduce or stabilize alcohol 
consumption (62). For some settings, integration of these strategies may be in addition to an already 
established culture and set of policies related to harm reduction. In other cases, specific attention 
may be needed to develop organizational harm reduction policies and ensure staff education in harm 
reduction.
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3.0 Implementing Temporary 
Supervised Consumption Services 
in Response to COVID‑19
Supervised consumption services provide monitored spaces where people consume illegal drugs 
without the risk of police intervention or criminal sanctions, in the presence of staff trained to 
respond in the event of an overdose or other adverse event. They also provide access to sterile drug 
consumption supplies and typically offer other health and social supports. Supervised consumption 
services are associated with reductions in overdose-related mortality and drug-related risks (e.g., 
syringe-sharing), increased access to social, health, and addiction-related services, and have not 
been shown to have a negative impact on public disorder or drug-related crime in the surrounding 
area (63,64).
3.1  SECURING AN EXEMPTION FOR AN URGENT 
PUBLIC HEALTH NEED SITE
In Canada, Health Canada grants exemptions to the Controlled Drugs and Substances Act to operate 
supervised consumption services. Applicants can apply to open either a supervised consumption 
site or an Urgent Public Health Need Site. Health Canada defines Urgent Public Health Need Sites 
(UPHNS) as spaces for people who use illegal substances to consume them and receive assistance 
in the event of an overdose (UPHNS are sometimes also referred to as overdose prevention sites 
(OPS) because, as OPS, they are meant to be temporary locations and low-threshold services which 
distinguish them from supervised consumption sites). Site staff monitor participants before, during, 
and after they consume drugs. Staff are prepared to give naloxone or other life-saving responses, as 
needed. Compared to supervised consumption sites that require going through a longer and more 
exhaustive exemption process (and possibly additional regulatory or policy processes at the provincial 
or territorial level), UPHNS can be established quickly as short-term responses to address urgent 
public health needs, such as the need for consumption spaces in an emergency or temporary shelter 
in the context of COVID-19.
UPHNS are intended to be short-term, targeted interventions. In the context of the current pandemic, 
the health of people who use substances is at risk due to concomitant threats of opioid-related 
overdose deaths and hazards related to illegal substances, as well as the spread of COVID-19. Often 
implemented rapidly to prevent the loss of life, UPHNS may have pared down service models compared 
PAGE 22  |   Supporting people who use substances in shelter settings during the COVID‑19 pandemic |  NATIONAL RAPID GUIDANCE
to longer term supervised consumption site models. While many supervised consumption sites offer 
a wider continuum of health and social services for people who use substances, UPHNS typically have 
less capacity to offer these ancillary supports. 
Prospective operators of both UPHNS and supervised consumption sites require exemptions under 
either subsection 56(1) or section 56.1, respectively, to protect participants and staff from criminal 
sanctions under the Controlled Drugs and Substances Act. Health Canada has established two possible 
avenues for prospective operators to apply for exemptions to legally operate UPHNS. 
First, in response to COVID-19, Health Canada issued temporary class exemptions to all Canadian 
provinces and territories in April 2020, enabling provincial or territorial Ministers of Health to approve 
UPHNS applications in their jurisdictions. Provinces and territories may have their own application 
process and criteria for prospective UPHNS operators. They are also able to further delegate UPHNS 
approval to municipalities. The class exemption enables a province or territory to allow their Ministry 
of Health, their Health Authorities, municipalities, or any other entity as the province or territory sees 
fit, to set up and administer the UPHNS on their behalf. The entity is authorized by the province or 
territory to set up and administer the UPHNS, however, the province or territory remains ultimately 
responsible for complying with the terms and conditions of the class exemption. Some provinces 
or territories may decide not to activate their class exemptions, and others may or may not grant 
other entities, such as municipalities, the permission to approve UPHNS applications. To obtain more 
information or to apply to operate UPHNS under a provincial or territorial class exemption, contact 
your provincial or territorial department of health. 
Second, prospective UPHNS operators can apply directly to Health Canada. The first step in this process 
is to request an application form from the Office of Controlled Substances by emailing hc.exemption.
sc@canada.ca. Applicants will receive instructions for completing the application and submit their 
completed information to the same email address. Health Canada prioritizes the review of these 
applications, and working closely with the applicant, aims to provide an authorization/response 
within 5 business days.
UPHNS applications submitted to the federal government typically include:
• Contact information of the applicant;
• Location of the proposed site; 
• Details regarding the services to be provided (e.g., the routes of consumption that will be 
permitted, the hours of operation, etc.); and
• Information on why the site is required (i.e., describe the urgent public health need that the 
site is addressing).
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Other information may be required by Health Canada in assessing temporary exemption applications. 
With regard to funding, Health Canada, has stated that at this time they will not fund supervised 
consumption sites or UPHNS, “however, due to the impacts of COVID-19 on communities and 
vulnerable populations, there may be other sources of funding available from community partners 
dealing with harm reduction, homelessness, community services and other donors. As examples, 
many cities and organizations have been provided federal funding for homelessness that could be 
potentially used to alleviate funding pressures for urgent public health need sites or supervised 
consumption sites” (65). 
In addition to securing federal legal exemptions, shelter operators should be aware that other 
administrative requirements (updates to insurance or other policies, etc.) may be needed to protect 
against potential liability in the event of an adverse event involving supervised consumption service 
participants or staff. Finally, it should be noted that staff who belong to professional colleges may have 
to comply with specific regulatory requirements when providing care to supervised consumption 
service participants. Staff should contact their professional college for more information on their roles 
and responsibilities, as required.
See the following resource for more information about the revised application process for UPHNS:
• Questions and Answers - Provincial/Territorial Class Exemptions: For Supervised Consumption 
Site Operators (65)
3.2  SETTING UP SUPERVISED CONSUMPTION 
SERVICES WITHIN A SHELTER SETTING DURING 
COVID‑19
There are many factors to consider when determining key attributes of supervised consumption 
services within shelter settings. Some considerations are outlined below.
Privacy. Where possible, supervised consumption services should be located in an area that protects 
privacy by limiting the visibility of participants entering and exiting the service by people in other 
areas of the shelter (66).  
Lighting. Proper lighting in all areas of the supervised consumption service is required to ensure the 
safety of participants and staff.
Centralized models. Supervised consumption services can be adapted to a range of contexts; there 
are precedents for integrating these services into hospitals (67), hotels temporarily housing people 
who are experiencing homelessness or housing vulnerability (68), shelters (69), mobile units (70), 
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and housing facilities (24,71). For shelters seeking to implement one or more centralized spaces 
for supervised consumption (e.g. all residents attend one or more designated areas dedicated to 
supervised consumption only), a large, closed-in space is recommended to help manage entry 
and flow of participants while maintaining physical distancing requirements (e.g. participants and 
staff remain two metres apart as much as possible throughout all areas of the service). However, if 
participants use the service alone (e.g. staff observe from behind a window or door), space for physical 
distancing is not required. In facilities where sufficient space is not available for physical distancing, 
continuous masking of staff and participants could be another option. Any supervised consumption 
service area should be easily observed by staff and large enough to meet applicable accessibility 
requirements and safety codes, and ensure emergency medical services (EMS) can access it in the case 
of a medical emergency. A separate, designated area could be included for screening participants for 
COVID-19 prior to them entering the supervised consumption service, if required. Staff should inform 
participants that in the event of an overdose or other medical emergency, the space will need to be 
quickly cleared of all other participants and staff not responding to the emergency to ensure safety 
and reduce potential risk of COVID-19 transmission. The space should be sufficiently separate (ideally 
enclosed) from other areas of the shelter to minimize the potential spread of aerosolized droplets 
in the event that a supervised consumption service participant is COVID-19 positive and requires an 
intervention, including certain methods of respiratory support, that are considered to be an aerosol-
generating medical procedure (AGMP; see section 3.3.5  Responding to Overdose within Supervised 
Consumption Services on page 36 for more information on AGMPs in supervised consumption 
services). All surfaces, including barriers separating patient areas and furniture, should be made of 
non-porous materials that can be easily cleaned (72).
Grouping participants depending on COVID‑19 status. With centralized supervised consumption 
service models, when feasible, there should ideally be separate services (with waiting, consumption, 
and monitoring areas) for each of the three populations at varying degrees of COVID-19 risk: [1] 
those who are asymptomatic, not under any public health directive to self-isolate, and not undergoing 
any investigations related to COVID-19; [2] those who are suspected of COVID-19 infection (e.g., 
suspected to be COVID-19 positive but awaiting test results) or who have had close contact with 
someone who is confirmed positive for COVID-19; and [3] those who are confirmed to be positive 
for COVID-19. Specific cohorts or participant groups within each setting should be determined in 
consultation with local public health and infection prevention and control experts and account for 
local COVID-19 epidemiology.  Grouping participants by their COVID-19 status aims to limit risk to 
other participants and shelter staff and conserve personal protective equipment (PPE) (73). See 
section 3.3.2  Screening Supervised Consumption Service Participants for COVID‑19 on page 27 
for information on screening participants for COVID-19.
Decentralized or dispersed model. Instead of one centralized area for supervising drug consumption 
episodes, shelter operators and medical teams may explore the possibility of providing a decentralized, 
‘bedside’ or ‘episodic’ supervised consumption service model where a participant consumes drugs 
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within their own designated area or room and are supervised by a staff member maintaining physical 
distancing and wearing the appropriate PPE (see section 3.3.3  Staff PPE on page 28 for information 
on PPE for staff). If there are multiple people staying together (e.g. couples, family members) peer-
witnessing and monitoring for overdose may be another practical option. Harm reduction supplies 
and sharps disposal containers could be distributed to participants to be stored with their personal 
belongings. This may be an especially useful option in medical isolation shelters with multiple separate 
areas for cohorting participants based on COVID-19 status. See COVID-19 Provincial Episodic Overdose 
Prevention Service (e-OPS) Protocol (74) from the British Columbia Centre for Disease Control for 
more information on implementing this kind of model.
Mode of administration. Ideally all common modes of drug administration (oral, intranasal, injection, 
and inhalation) should be accommodated. The majority of supervised consumption sites in Canada 
accommodate injection, oral, and intranasal routes. There are currently two supervised consumption 
sites (one in Lethbridge, Alberta and one in Saskatoon, Saskatchewan) that are federally-exempted to 
monitor drug consumption via inhalation/smoking. Both of these facilities have specially ventilated 
rooms that follow occupational health and safety protocols to protect staff and other participants 
from exposure to secondhand smoke. While this is unlikely to be practical in UPHNS scenarios, there is 
precedence for supervising inhalation activities in a designated outdoor area (75). Pop-up inhalation 
tents could be established in courtyards or adjacent outdoor areas within view of staff. However, 
operators should note that outdoor locations are not ideal because concrete or asphalt flooring does 
not facilitate thorough cleaning and disinfecting.
Hours of operation. Supervised consumption services operating 24 hours per day, seven days per 
week provide the most accessible service for residents. However, depending on the specific needs 
of the community, available resources and demand, this schedule may not be practical. Operators 
should have in place procedures for monitoring high-risk areas within and around the shelter premises 
for potential unobserved overdoses amongst residents consuming substances outside of supervised 
consumption service operating hours. 
Hand hygiene. Supervised consumption service staff and participants need to have access to hand 
hygiene sinks and/or a Health Canada-approved hand sanitizer (with a minimum of 60% ethanol 
content) (76). Participants should perform hand hygiene, either by washing their hands with soap 
and water for 20 seconds, or applying hand sanitizer prior to entering the supervised consumption 
service, before and after drug consumption, and upon leaving the supervised consumption service. 
Staff should perform hand hygiene regularly, including before and after any physical contact with any 
participants or their belongings. Posters for HandRub and HandWash procedures (77,78) should be 
posted at all hand hygiene stations in the supervised consumption service.
Surface and environmental cleaning. The supervised consumption service should be implemented in 
an area of the shelter amenable to regular cleaning. A process should be developed for cleaning that 
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delineates roles and responsibilities, frequency, and tracking. The process should include cleaning 
and disinfecting (two-step process) all surfaces and reusable equipment contacted by participants 
regardless of their COVID-19 status, between each participant. Other high touch areas and shared 
spaces should be cleaned frequently throughout the day and this should be documented. A Health 
Canada approved disinfectant with activity against COVID-19 should be used (76,79).
Building trust with people who use drugs. Operators should be mindful that they are introducing a 
new service which, in some cases, could mean an organizational policy change from abstinence to 
embracing a wider range of harm reduction practices. It may take time to build trust amongst people 
who use substances who may be understandably wary of the supervised consumption service at first. 
One strategy to better understand the needs of the people who use the service is to implement a 
community advisory committee of people who access the service. Hiring people with lived and living 
experience also helps build trust. For more information on effectively engaging and employing people 
who use substances see section 2.3  Guiding Principles on page 17. 
Preventing overdose in adjacent shelter areas. Even with the implementation of supervised 
consumption services in shelter settings, bathrooms and other private or semi-private areas may still 
be used to consume substances to avoid the perceived or real threat of punitive measures from staff 
(e.g., eviction), when the supervised consumption service is closed or at capacity, or in an effort to 
conceal drug possession or use from peers (19,80,81). Drug use within bathrooms or other areas can 
result in unhygienic practices and increase the possibility of unwitnessed overdoses (82). Therefore, 
whether or not a supervised consumption service is operational, it is recommended to include regular 
monitoring and safety checks of bathrooms and other high-risk areas. Bathrooms should ideally have 
locks that can be opened from the outside and/or a door which unlocks after a fixed amount of time 
to allow staff to check on occupants while maintaining the individual’s privacy and dignity as much as 
possible (83). Secured and tamper resistant sharps containers should be installed in bathrooms and 
other areas where substance use could occur, and overdose prevention information posted (84–86).
3.3  SUPERVISING CONSUMPTION IN SHELTERS 
DURING COVID‑19
3.3.1  Screening Supervised Consumption Service Staff for 
COVID‑19
Every supervised consumption service staff member should be screened for COVID-19 as they arrive 
at work according to the standard screening questionnaires and procedures recommended by local 
public health authorities. Staff who experience new symptoms or meet other high-risk criteria should 
be immediately placed on leave until it is deemed safe (according to local public health guidance) for 
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them to return. They should be referred for testing and advised of procedures for self-isolation and 
available financial benefits to offset lost income, as required. Operators should consider scheduling 
cohorts of staff together on the same rotations to help mitigate potential staff shortages if an outbreak 
occurs by potentially limiting the number of staff exposed.
3.3.2  Screening Supervised Consumption Service 
Participants for COVID‑19 
Staff should warmly greet each supervised consumption service participant in the intake area. 
Participant screening should be done either from behind a physical barrier (e.g., plexiglass or by 
a call-in from outside), with physical distancing, or with appropriate PPE (see section 3.3.3  Staff 
PPE on page 28 for information on PPE). Staff members should be knowledgeable about harm 
reduction as an approach to care, and be able to provide safer drug use education and infection 
prevention guidance in the context of COVID-19 to all participants presenting for screening. Supervised 
consumption service participants should be screened for COVID-19 as they arrive according to the 
standard screening questionnaires and procedures recommended by local public health authorities. 
Examples of screening procedures developed in Ontario are listed in section 5.0 Further Reading and 
Resources on page 56 at the end of this document (87,88). Local recommendations may change 
regularly to reflect COVID-19 epidemiology, and supervised consumption service policies should be 
updated regularly to reflect these changes as needed.
If a participant is suspected of having COVID-19 (e.g., due to close contact with a confirmed COVID-19 
case), provide a medical-grade mask for the participant to wear within the supervised consumption 
service. Depending on the local prevalence of COVID-19, staff might consider providing a medical-
grade mask to all participants, regardless of COVID-19 tests or risk factors. All staff and participants 
should be advised on other infection prevention and control measures they are required to take (e.g., 
cough and sneeze into a tissue or their elbow, hand hygiene, physical distancing (35)) to minimize 
transmission of COVID-19 (88). Staff members should work closely with public health officials to 
facilitate formal COVID-19 screening and testing, and referral to appropriate self-isolation support. 
If the supervised consumption service has separate areas for people who are positive for COVID-19, 
have had a high-risk exposure or are undergoing a relevant investigation, physical distancing between 
participants should continue and medical-grade masks or other PPE should be provided to these 
participants according to local public health guidance. Alternatively, sites could provide single use 
rooms or a partitioned area with windows or sightlines for monitoring, if feasible. Cohorting of staff 
to these participant groups is strongly encouraged.
It is important to note that people who are not showing symptoms might still be positive for COVID-19 
and transmit the virus despite being asymptomatic (89,90). Therefore, regardless of whether COVID-19 
status is known or unknown, it is imperative that sites maintain the proper physical distancing between 
PAGE 28  |   Supporting people who use substances in shelter settings during the COVID‑19 pandemic |  NATIONAL RAPID GUIDANCE
each supervised consumption service participant, perform hand hygiene regularly, and thoroughly 
clean each consumption space (and any other areas touched by participants) after each use in order 
to minimize transmission of the virus (see section 3.2  Setting up Supervised Consumption Services 
within a Shelter Setting During COVID‑19 on page 23 for more information on hand hygiene and 
surface and environmental cleaning).
3.3.3  Staff PPE
Specific staff PPE requirements in each shelter setting should be determined in consultation with local 
public health authorities and account for local COVID-19 epidemiology, participant demographics, 
supervised consumption service infrastructure, knowledge and training of staff, PPE supplies, and 
employer policies. Operators should be continuously reviewing and updating PPE requirements, as 
necessary, to ensure they are in line with the best available science and public health guidance at all 
times. Seeking expert infection prevention and control consultation is strongly advised. Staff who may 
provide (or anticipate providing) care to participants within two metres need to be trained in PPE use, 
including proper donning and doffing technique and hand hygiene. This includes anyone who might 
respond to an overdose or medical emergency. 
There are multiple methods for determining PPE requirements, including by participant COVID-19 
status or task performance; Table 1 provides example guidance on selecting PPE intended for general 
community (i.e. non-healthcare) settings. Note that this approach to selecting PPE may differ from 
that taken in medical isolation shelters where patients with confirmed COVID-19 positive status are 
being supported by healthcare staff. Always defer to local public health guidance in determining the 
appropriate PPE for staff in your setting.
Staff performing COVID-19 risk factor screening who cannot do so from behind a barrier, or while 
maintaining physical distancing, should wear a medical-grade mask and eye protection. Please 
see section 3.3.2  Screening Supervised Consumption Service Participants for COVID‑19 on page 
27 and contact your local health authority or provincial/territorial health department for local 
procedures. Due to the risk of asymptomatic COVID-19 transmission and other communicable diseases 
(89,90), staff should always utilize “routine practices” (called “standard precautions” by the World 
Health Organization (91)). This includes point-of-care-risk assessment, frequent hand hygiene, and 
environmental cleaning (92). Subsequent PPE use should be dictated by the task being performed. 
In most circumstances, PPE for participant interaction can be selected based on their COVID-19 risk 
factors (see section 3.3.2  Screening Supervised Consumption Service Participants for COVID‑19 on 
page 27) and task-based risks, per the matrix below (79,88,93).
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Table 1. Matrix on selecting PPE for general community (non‑
healthcare) settings based on participant risk factors and 
task‑based risks1
PARTICIPANT RISK CATEGORY MINIMALLY INVASIVE TASKS*
INVASIVE TASKS WITH POSSIBLE 
CONTACT WITH PARTICIPANTS’ 
BODILY FLUIDS^
No risk factors for COVID-19 Medical-grade mask
Consider eye protection (see text 
for details)
Medical-grade mask
Gloves if hands exposed to non-intact 
skin or bodily fluids
Gown if clothing exposed to bodily 
fluids
Eye protection if face exposed to 
bodily fluids
Risk factors for COVID-191 Medical-grade mask and eye 
protection
Gown, gloves, medical-grade mask, 
eye protection
* Minimally invasive tasks: talking to participant, contact with intact skin, vital sign monitoring, simple assessments, 
administering medications, distributing food/supplies
^ Invasive tasks: Nasopharyngeal swab collection, full physical exam, injectable medications and any other task with 
possible contact with bodily fluids including saliva, sputum, nasal secretions, vomit, urine, feces, blood, etc.
1 This matrix is provided as an example of existing guidance for non-healthcare settings. PPE advice and 
recommendations vary according to specific jurisdiction, setting and service model. Operators should defer to local 
public health guidance in determining staff PPE requirements. Given the evolving nature of the COVID-19 pandemic 
and associated knowledge base, PPE requirements should be continually reviewed and updated as required.
If local prevalence of COVID-19 is high, such as in a community or shelter outbreak setting, it may 
be reasonable to select PPE from the matrix as though all patients have risk factors for COVID-19 
(i.e., bottom row). When performing aerosol generating medical procedures (AGMPs; e.g., certain 
respiratory interventions (94)), staff should use Contact & Droplet precautions (gown, gloves, mask, 
eye protection) and a fit-tested N95 respirator instead of a medical mask for those with COVID-19 risk 
factors (see section 3.3.5  Responding to Overdose within Supervised Consumption Services on page 
36 for detailed guidance on responding to overdoses and PPE requirements).
During the COVID-19 pandemic, continuous masking of all staff could be considered in the supervised 
consumption service when physical distancing cannot always be maintained with participants and 
other staff (95). The mask should be removed if wet or soiled with proper doffing technique including 
hand hygiene after handling the mask (95,96). Additionally, use of eye protection for all participant 
care could be considered in areas with high community prevalence of COVID-19 and can be worn 
continuously. Gowns and gloves should be changed between every participant encounter, with hand 
hygiene performed (96). Continuous PPE use strategies should follow local or international guidelines 
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and may reduce the need to repeatedly don and doff PPE, and thereby conserve overall PPE supplies 
(91). While these continuous PPE strategies have been employed in health care facilities in the 
COVID-19 context, there is limited evidence on their utility in community settings. Consultation with 
local public health authorities should be considered to help guide these strategies. 
3.3.4  Monitoring Consumption and Providing Care within 
Supervised Consumption Services
Supervised consumption services should always be offered in a culturally safe manner that is consistent 
with a harm reduction and trauma-informed approach (97). Culturally safe care focuses on strategies 
that help build relationships with participants and minimizes harms stemming from drug-related 
stigma and discrimination (98). Additionally, throughout each visit, staff and participants need to follow 
proper hand hygiene, and other sanitation protocols to minimize the risk of COVID-19 transmission. 
Please see section 3.2  Setting up Supervised Consumption Services within a Shelter Setting During 
COVID‑19 on page 23 for more details. Depending on staffing, supervised consumption service 
capacity, and PPE availability, operators should consider incorporating any of the following ancillary 
supports that are commonly offered in other supervised consumption services:
• basic medical services (e.g., first aid, naloxone training, wound care),
• demonstration of, and education on, safer consumption and injection techniques,
• peer support or outreach from people with lived or living experience of substance use,
• referrals to substance use treatment (e.g., opioid agonist therapy, specialty addiction recovery 
programs), and/or
• referrals to other health and social services (e.g., income support, housing, care planning and 
case management).
Staffing
The recommended staffing ratio is dependent on a number of factors, including the supervised 
consumption service layout (e.g., how many spaces and rooms), capacity of the supervised 
consumption service (e.g., how many participants can be in the site at once), and physical size of the 
site. Operators should also try to anticipate temporary periods of increased demand, such as in the 
week following disbursement of income support cheques (99) or if a sudden increase in the toxicity 
of the illegal drug supply is detected. At a minimum, there should be a staff member present in each 
separate area to monitor and respond to participants experiencing an overdose or other adverse 
medical event. Participants should be visible by staff at all locations within the site.
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At all times, staff who are trained and experienced in PPE donning and doffing and recently N95 fit 
tested should be identified to respond to overdoses at the site. These individuals should have access 
to properly fitted N95 masks when responding to an overdose to ensure staff safety if an AGMP 
is required as part of the overdose response (see section 3.3.5  Responding to Overdose within 
Supervised Consumption Services on page 36 for detailed guidance on PPE required for responding 
to overdoses in supervised consumption services).
Across Canada, a variety of staff with different expertise are employed in supervised consumption 
services and most have interdisciplinary teams. Services may be staffed by people with lived and living 
experience of substance use, and those trained in nursing, social work, addiction counselling, as well 
as EMS personnel (herein referred to as staff). Employing people with lived or living experience is an 
essential strategy for facilitating meaningful uptake and engagement with the service (24). Guidance 
is available for employers on hiring, fairly compensating, and supporting staff with lived or living 
experience of substance use and it is strongly recommended that operators employ people with lived 
or living experience whenever possible (100,101). Regardless of discipline, all staff should be trained 
in harm reduction, cultural safety, trauma informed care/practice, basic first aid, overdose response 
(e.g., naloxone administration, cardiopulmonary resuscitation [CPR]), and infection prevention and 
control procedures. Staff training and ongoing support is essential for creating safe work environments 
and providing care that is sustainable. One practical strategy is a beginning of shift and end of shift 
team meeting or handover to provide opportunities to debrief and share pertinent information.
Pre-consumption
Participants should wait in a designated area until there is a vacant consumption space open. Staff 
members could place markers on the floor or chairs spaced two metres apart to ensure physical 
distancing requirements are met. Staff could explain to participants that wait times may be extended 
due to the reduced number of consumption spaces to comply with physical distancing requirements. 
Ideally large personal belongings should not be brought into the supervised consumption service, and 
staff should consider providing participants with a single use plastic bag and designated area to store 
their larger and smaller personal belongings while at the site. When there is a consumption space 
available, a staff member can screen the next participant (see section 3.3.2  Screening Supervised 
Consumption Service Participants for COVID‑19 on page 27), and gather any information required 
for intake. Intake procedures and information collected vary across supervised consumption services, 
and ultimately are determined by local needs, staff capacity and specific regulatory context (see 
section 3.4 Reporting and Evaluation on page 39 for more information). It is helpful for staff to 
record or be aware of the drugs the participant is planning on using and when and what they last 
used to assess their relative risk of overdose, and the involvement of any polysubstance use. If drug 
checking services are available (e.g., strips to test for the presence of fentanyl, or an FTIR or mass 
spectrometer), participants may test their drugs before or after entering the consumption area and 
preparing their drugs for consumption, depending on checking protocols. At the participant’s first visit 
PAGE 32  |   Supporting people who use substances in shelter settings during the COVID‑19 pandemic |  NATIONAL RAPID GUIDANCE
to the supervised consumption service, they may be asked to sign a participant agreement or give 
verbal consent, which explains site procedures and the rights of participants and staff. 
Depending on which routes of consumption were exempted under the Controlled Drugs and Substances 
Act, participants can consume their drugs through injection, intranasal, and oral routes at the booths 
or tables set up in the site, or through inhalation in specially ventilated rooms or outside (see section 
3.2  Setting up Supervised Consumption Services within a Shelter Setting During COVID‑19 on 
page 23). The booths/tables and chairs should be sturdy and comply with the relevant infection 
prevention and control protocols (e.g., should be able to be cleaned and disinfected easily (72)); 
chairs should be maneuverable and light-weight so they can be easily moved in medical emergencies. 
Each consumption space should be a minimum of two metres apart. If using existing infrastructure, 
participants can be placed at every other booth/table to ensure sufficient distancing.
Consumption
To limit the potential spread of COVID-19 between participants, staff members should first perform 
hand hygiene then collect and distribute sterile drug consumption equipment to participants while 
maintaining appropriate physical distancing. The participant should complete hand hygiene prior to 
accepting these supplies (see section 3.2  Setting up Supervised Consumption Services within a Shelter 
Setting During COVID‑19 on page 23 for more information on hand hygiene protocols). Operators 
will need to secure access to sterile harm reduction supplies (through specialized distributors) and 
medical waste disposal services. Staff members can either have kits of supplies prepared in advance 
to provide to each participant or can ask the participant about the equipment they require for their 
consumption and distribute it accordingly. Available equipment should include:
• needles and syringes in a variety of gauges and sizes,
• tea light candles and lighters (if matches are used, ensure they do not become a fire hazard),
• disposable cookers, 
• filters (if purchased separately from cookers, use tweezers to extract filters from the bag and 
place into a single-use container for the participant),
• sterile and disposable water, 
• acidifier (e.g., ascorbic  acid),
• alcohol swabs,
• disposable or participant-specific tourniquets,
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• disposable tray (for distribution of supplies),
• straws (for intranasal consumption),
• foil or other disposable container to hold drugs (for intranasal consumption), 
• borosilicate (e.g., Pyrex®) glass pipes, ball pipes, or stems (for inhalation),
• mouthpieces (for inhalation), 
• metal pipe screens (for inhalation), 
• mirrors (handheld), 
• condoms and personal lubricant, and
• disposal containers.
Supplies should be available both for use within the supervised consumption service and provided 
on demand to participants to take with them. Detailed guidance on distribution of harm reduction 
supplies are available in the following documents:
• Best Practice Recommendations for Canadian Harm Reduction Programs that Provide Services 
to People who use Drugs and are at Risk for HIV, HCV, and Other Harms: Part 1; Working Group 
on Best Practice for Harm Reduction Programs in Canada (12)
• Best Practice Recommendations 2 for Canadian Harm Reduction Programs that Provide Service 
to People who use Drugs and are at Risk for HIV, HCV, and Other Harms; Working Group on 
Best Practice for Harm Reduction Programs in Canada (13)
Staff members should not collect used equipment; instead, staff should direct participants to dispose of 
their equipment in designated disposal bins. Participants should also have the opportunity to dispose 
of other used equipment (from prior consumption episodes outside of the supervised consumption 
service). Operators should refer to the shelter’s biohazard disposal policy or consult their local public 
health authority or health department for jurisdiction-specific guidance in the context of COVID-19.
Many supervised consumption services have time limits for participants in the consumption area to 
minimize wait times for other participants. Staff members should gently remind a participant that 
their time is up but allow for a few extra minutes when feasible, and provide safer drug use education 
to participants where appropriate while working in the consumption room. Operators will need to 
determine which injection-related supports will be available to participants, and clearly communicate 
this to staff and participants. Possible supports include staff members helping participants find veins 
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for injection (e.g., using their fingers or online apps), preparing drugs, and peer-assisted injection. 
Peer-assisted injection (also known as peer assistance) is when a friend or partner (injector), who 
is not a staff member working at the supervised consumption service, helps a participant (injectee) 
inject their drugs by directly administering the injection. Health Canada has specific requirements for 
peer-assisted injection when it occurs within federally exempted UPHNS or supervised consumption 
services. By definition, the injector will not be able to maintain two metres distance from the injectee, 
so if the injector and injectee are in a close relationship through which they are functionally sheltering-
in-place together, then PPE is unlikely to be required (e.g., intimate partner, family member, room or 
bunk mate, or other recent close personal contact within two metres without PPE). However, if the 
injector and injectee are not in such a relationship and have not been in close proximity to each other, 
they should be provided with the appropriate PPE according to local health authority guidance. This 
may include gown, gloves, medical-grade mask, and eye protection. The injector and injectee should 
both wash their hands upon entering the consumption space and before drug consumption (see 
section 3.2  Setting up Supervised Consumption Services within a Shelter Setting During COVID‑19 on 
page 23 for details on hand hygiene). Where possible, a table and chair with generous space should 
be reserved for peer-assisted injection that allows adequate physical distancing from other injection 
booths. If the injector is planning to inject as well, it is suggested that the injector inject the injectee, 
the injectee leave the consumption area, and then the injector injects themselves, either at the same 
table or a different table depending on their preference. The injector must follow the direction and 
guidance of the injectee. At least one staff member must observe the entire peer-assisted injection 
process and ensure the injectee is in control of the injection process. In federally exempted services, 
the injectee signs an agreement accepting liability in the event of a negative outcome, and some 
operators also require the injector to sign a waiver as well.
Post-consumption
After participants have finished consuming drugs, they would ideally be observed in the monitoring 
area for a minimum of fifteen minutes to ensure they do not overdose. Physical distancing and 
recommended PPE must be maintained in the monitoring area; chairs should be placed two metres 
apart and staff should facilitate participant flow through this area. Snacks (e.g., coffee, granola bars) 
are typically offered in the monitoring area but should not be provided as self-serve options and 
should be individualized and prepacked to prevent COVID-19 contamination and transmission. Post-
consumption monitoring provides an opportunity to offer sterile drug consumption supplies for 
participants to take with them when they leave, which can be placed in a bag to ensure privacy along 
with personal sharps disposal containers. It is also strongly recommended that all participants be 
trained in naloxone administration and that naloxone kits be provided to every participant. Check 
with your local community-based naloxone program to ensure trainers have the most up-to-date 
information about providing CPR and administering naloxone in the context of COVID-19. An example 
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of newer guidance for naloxone program participants in Alberta is cited at the end of this document 
(102). The post-consumption area also provides an opportunity to offer harm reduction education 
and referral to treatment programs, health care, and social and cultural supports. 
Whenever possible, staff should discuss harm reduction practices with participants, including advice 
on preventing COVID-19 transmission. This could include tips for:  
• Maintaining proper hand hygiene by washing hands often with soap and water, or if hand 
washing facilities are not available, alcohol-based hand sanitizer (staff should be aware of the 
risks of consuming hand sanitizer as a source of non-beverage alcohol and advise participants 
as appropriate (103)).
• Not sharing any drug equipment (e.g. pipes) or cigarettes.
• Disinfecting packaging of drugs and equipment handled by other people.
• Preparing your own drugs.
• Preparing and consuming drugs on a sanitized surface.
• Not consuming alone but maintaining physical distancing recommendations whenever 
possible.
• Having more than adequate harm reduction supplies (e.g., drug consumption equipment, 
prescriptions, naloxone) to last the individual and other potential users two weeks, whenever 
possible.
• Reducing drug smoking when possible, or consuming drugs through lower-risk non-inhalation 
routes (e.g., oral or intranasal consumption), as COVID-19 infection impacts the respiratory 
system.
• When experiencing new symptoms associated with COVID-19, trying to strictly avoid other 
people as much as possible to reduce the potential spread of infection.
• If providing rescue breaths, use the mask provided in the naloxone kit with the understanding 
that this may not protect you from COVID-19. 
People who use substances or are experiencing homelessness or housing vulnerability may not be 
able to follow all of the recommended harm reduction practices; staff should emphasize following 
these practices as much as possible to protect against COVID-19 infection. Examples of resources that 
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outline potential harm reduction practices in the context of COVID-19 include:
• COVID-19: Advice for People who use Drugs; Canadian Association of People who use Drugs, 
International Network of People who use Drugs, European Network of People who use Drugs 
(104)
• COVID-19 & Drug Use: Tips & Tricks; Harm Reduction Victoria (Australia) (105)
• COVID-19: Harm Reduction and Overdose Response; BC Centre for Disease Control (106) 
• COVID-19 Planning for the Substance Dependent; Harm Reduction Victoria (Australia) (107)
• COVID and Harm Reduction; DTES Collaborative (108)
• COVID-19 Stimulant Use, and Harm Reduction; Resolve to Save Lives - Vital Strategies, Harm 
Reduction Coalition, Higher Ground Harm Reduction, Reynolds Health Strategies (109) 
• Guidance for People who use Substances on COVID-19 (Novel Coronavirus); Yale Program in 
Addiction Medicine, Global Health Justice Partnership & Crackdown (110)
• Harm Reduction Tips during Corona Virus; Somerset West Community Health Centre (111)
• Safer Drug Use During the COVID-19 Outbreak; Harm Reduction Coalition & Vital Strategies 
(United States) (112)
Contact your local harm reduction program, public health authority, or health department for 
recommendations specific to your jurisdiction.
3.3.5  Responding to Overdose within Supervised 
Consumption Services
After supervising drug consumption, staff need to monitor participants at all times for the common 
signs of an opioid overdose: pinpoint pupils, respiratory depression, and unconsciousness (113). 
However, it is important to note that not every participant experiencing an overdose will display 
these symptoms; atypical symptoms such as muscle rigidity or involuntary movements have been 
documented with increasing frequency and can complicate overdose interventions (114,115). Special 
attention is required when monitoring participants, as physical distancing and PPE requirements can 
complicate the ability to recognize an overdose (e.g., unable to see blue lips if the participant is wearing 
a mask, difficult to see pinpoint pupils while maintaining two metre distance from participants). In 
the event of an opioid overdose occurring at the site, all other participants and staff not responding 
to the overdose need to exit the area. Operators should have an overdose response protocol, 
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outlining the preferred response to an overdose based on the resources available at the site and local 
current guidance for infection prevention and control. This protocol should reflect the best available 
COVID-19-specific evidence, be updated as new evidence becomes available, and should outline the 
interventions available to staff, the equipment (including PPE) necessary, roles and responsibilities 
(taking into account training and background), as well as the thresholds for each intervention. Ongoing 
staff training on this protocol is essential. Possible interventions, including some that are suspected or 
confirmed AGMPs (see below), are:
• Providing CPR, with or without rescue breaths.
• Providing oxygen, administered by high flow oxygen, bag valve mask, or non-rebreather 
equipment.
• Providing naloxone, administered intranasally or intramuscularly.
• Use of a portable automated external defibrillator (AED).
• Calling 911.
Depending on the severity, staff may need to try multiple interventions to successfully reverse the 
overdose. Due to the risk of exposure to participant blood or bodily fluids when responding to an 
overdose, staff should don PPE regardless of COVID-19 risk factors, including a medical-grade mask, eye 
protection, gloves, and a gown according to the principles of point-of-care risk assessment (79,92,96). 
Providing CPR and some types of oxygen delivery may be considered AGMPs (73,88,96,102,116–
122). AGMPs are “any procedure conducted on a patient that can induce production of aerosols of 
various sizes”, and include non-invasive ventilation interventions (e.g., bag-valve-mask) (79). AGMPs 
are considered a high-risk intervention as they present a risk for airborne transmission of pathogens, 
including COVID-19. As this is a rapidly evolving area of medical science, operators should contact 
their local public health authority or health department for specific guidance on which interventions 
are considered AGMPs, particularly for cardiopulmonary resuscitation as there is a lack of consensus 
across jurisdictions regarding its role as an AGMP (94). Operators may also consider consulting 
the shelter’s first aid and CPR policies specific to COVID-19 for further guidance. When providing 
an intervention considered to be an AGMP, fit tested N95 respirators are recommended instead of 
medical-grade masks when the participant is known or suspected to have COVID-19 to reduce the 
risk of transmission (73,96,118–120). Staff trained in the use of this specialized equipment should be 
present. 
Staff need to respond to overdoses quickly, so the appropriate PPE needs to be easily accessible from 
all locations in the site. If the appropriate PPE is not available, each staff member should determine 
the level of intervention they are comfortable providing by weighing professional and ethical 
obligations (where appropriate) and potential risk of harm. Organizational policies may also offer 
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specific guidance to staff in this situation. For participants who are pulseless, placing a barrier over 
the participant’s face (e.g., a folded towel or pillow case, medical-grade mask) could be considered as 
a transmission risk mitigation strategy to allow chest-compressions to be performed until responders 
in appropriate PPE can take over care.
Following an overdose response involving an AGMP, staff should disinfect the area with Health Canada 
approved disinfectant. Some guidelines recommend waiting one hour “to allow aerosolized particles 
to drop” (96), although the risk posed by aerosolization is dependent on the building ventilation and 
filtration system (123). If the overdose response included an AGMP intervention, the surrounding 
two metre radius should also be disinfected (117). Anything that is unable to be properly disinfected 
(including PPE) should be properly disposed of. Operators should consider disposing of contaminated 
PPE in a biohazard bag, sealed inside another bag; refer to the shelter’s biohazard disposal policy or 
contact your local public health authority or health department for jurisdiction-specific guidance. No 
other participants should enter the area until the disinfection is complete (117). 
If possible within the space and with adequate staff observation, having consumption tables/booths 
in multiple separate rooms could facilitate continual access to the service by allowing consumption to 
continue in the other rooms while addressing an overdose. If all consumption tables/booths are in the 
same room, the entire consumption area will need to be closed until the overdose has been reversed 
and disinfection has been completed.
Examples of health authority and provincial resources on responding to an overdose within a 
supervised consumption service are provided below. However, as science and best practice in this area 
are still evolving, operators should consult local health authorities for the most up-to-date guidance. 
• COVID-19: Community Members Responding to Overdose; Vancouver Coastal Health (124)
• COVID-19 Guidance: Consumption and Treatment Services (CTS) Sites; Ontario Ministry of 
Health (88)
• COVID-19 Protocol for Aerosol-Generating Medical Procedures (AGMP) in The Works 
Supervised Injection Site (SIS) Environment; Toronto Public Health, Public Health Ontario (117)
• COVID-19: Responding to Opioid Overdoses in Overdose Prevention Services (OPS) and 
Supervised Consumption Sites (SCS); BC Centre for Disease Control, BC Ministry of Health 
(125) 
• Opioid Poisoning Response and COVID-19; Alberta Health Services (102)
• VCH Overdose Response in Overdose Prevention Sites and Supervised Consumption Sites for 
COVID-19; Vancouver Coastal Health (96)
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3.3.6  Staff Exposures to COVID‑19
Ensuring appropriate participant and staff screening procedures, PPE training and access, physical 
distancing, and cleaning procedures will minimize risk of exposure to staff. However, staff should have 
clear guidance on decontamination and reporting protocols in the event that they are exposed. Major 
breeches could adversely affect service delivery as a large number of staff may be forced to be off 
work. Any exposure to COVID-19 should be reported to the local public health authority.
Local public health may require that staff who are exposed to known or suspected COVID-19 participants 
or colleagues without appropriate PPE or physical distancing (e.g., providing care to a participant who 
is positive for COVID-19 without a medical-grade mask, or responding to an overdose by providing 
an AGMP to a participant with COVID-19 while not wearing a fit-tested N95 respirator) are excluded 
from work. Those excluded from work should be instructed to self-monitor for the development of 
new symptoms, self-isolate, and seek further direction from local public health authorities. Referral 
to available psychological and financial supports may also be considered.
3.4 REPORTING AND EVALUATION 
The government or entity (see section 3.1  Securing an Exemption for an Urgent Public Health Need 
Site on page 21) that issued the exemption, the funders, or other authorities may require reporting 
on supervised consumption service outputs and activities and aggregate demographic information 
of participants. Data collection should not impede service delivery, particularly in the context of an 
urgent pandemic-related response. However, where possible, operators should be prepared to collect 
and report the following minimum data elements:
• the average number of visits per day, 
• the number of overdoses/drug emergencies, and 
• the aggregated demographics of the participants, including age and gender.
If the site permits peer-assisted injection, the aggregate demographic information should include that 
of both the injector and the injectee. Operators should report this information in aggregate only to 
protect the privacy of injectors and injectees.
Operators may consider collecting data on the average number of unique visitors per day. To track 
unique visitors, staff will need to provide a unique identifier to each participant upon their initial 
presentation to the site. This identifier will be provided at each subsequent visit, so it is important to 
choose an identifier that the participant will remember while retaining their anonymity. 
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Operators may also consider tracking information on utilization of available services within the site 
(e.g., number of drug checking episodes, number of consumption episodes, number of referrals to 
other services). Other data elements that are collected at existing supervised consumption services 
include the self-reported drug that participants consume on site, the route of administration of each 
consumption episode, and details on overdose interventions and other direct health care provided.
Depending on the capacity of each site, there are a few possible avenues for collecting this information. 
Staff can record the data on paper, which can be collated later into a secure database, or within a 
software program such as Microsoft Excel or Access (see Appendix 1: Example Form for Supervised 
Consumption Service Data Collection on page 57).
If operators have the capacity, they should consider conducting evaluation or quality improvement 
activities at their site. Evaluations are often not required by the government body that provided 
the exemption, the funders, or other health authorities, but may be useful for demonstrating the 
effectiveness of the site in supporting participants in complying with public health recommendations, 
determining participant satisfaction with the service, and facilitating opportunities for service 
improvement and expansion to other emergency shelter settings.
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4.0  Providing Addiction Treatment 
and Pharmacotherapy in Shelter 
Settings
4.1  INCREASED RISK OF ADVERSE OUTCOMES 
FOR PEOPLE WHO USE SUBSTANCES AND ARE 
EXPERIENCING HOMELESSNESS DURING THE 
COVID‑19 PANDEMIC
People with substance use disorders residing in shelter settings may experience difficulty accessing 
legal and/or illegal drugs during the COVID-19 pandemic. Physical distancing requirements may make 
obtaining substances more difficult, and those purchasing illegal drugs are at risk of overdose, and 
exposure to and transmission of COVID-19. Leaving a shelter to obtain illegal or legal substances 
while under a directive to quarantine or self-isolate may contravene public health orders. Face-to-face 
interactions to purchase drugs serve as opportunities for direct transmission, and items exchanged 
(e.g., drugs, money) could serve as avenues for viral transmission. Further, shelter residents faced with 
income instability may participate in sex work, panhandling, or other income-generating activities 
that increase transmission risks for themselves and others (see (126) for more information on sex 
work and COVID-19). 
Pandemic-related border closures and supply disruptions may further complicate access to drugs, 
potentially increasing levels of drug adulteration or contamination, making the potency and toxicity 
of the illegal market even less predictable (5,127). Abrupt cessation or reduction of substance use 
can lead to withdrawal symptoms that vary in severity and presentation according to substance, the 
typical frequency of use, and dose consumed. Withdrawal from tobacco and cannabis can result in 
non-life-threatening withdrawal symptoms that cause significant discomfort (128). Withdrawal from 
opioids (e.g. fentanyl, heroin, hydromorphone, morphine) can lead to extreme discomfort though 
generally does not cause serious medical complications (128). Stimulant (e.g. methamphetamine, 
cocaine) withdrawal can result in agitation and irritability, or conversely depression and increased 
sleeping. Benzodiazepine and alcohol withdrawal, in severe cases, can result in potentially life-
threatening symptoms that require emergency medical care (e.g., seizures, delirium, hallucinations, 
extreme agitation, and fluctuations in body temperature and blood pressure) (129). 
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Periods of abstinence from substance use can lead to reduced physiological tolerance (130). Risk 
of mortality may be seven to twelve-fold for some people who use substances in the immediate 
period following a return to substance use (131–133). Complicating this situation is the fact that 
some withdrawal syndromes can mimic the symptoms of COVID-19. For example, opioid withdrawal 
often presents as influenza-like illness (e.g. runny nose, chills, gastrointestinal upset, fatigue). This 
may complicate screening and isolation protocols and increase the risk of COVID-19 transmission if 
symptoms of opioid withdrawal are mistaken for influenza-like illness, and potentially lead to exclusion 
from shelter services or inappropriate cohorting of COVID-19 negative people with others who are 
COVID-19 positive or at high-risk of COVID-19 infection.
4.1.1  Overview of Substance Use Disorder Treatment and 
Risk Mitigation Strategies for Supporting People who 
use Substances in Shelter Settings During the COVID‑19 
Pandemic
Supporting shelter residents in reducing or stabilizing their substance use and preventing withdrawal 
and overdose is thus critical for preserving their health and wellbeing and reducing strain on shelter 
staff and the health care system. This may be achieved through the provision of a range of on-site or 
off-site substance use supports.
The following sections outline: [1] evidence-based first- and second-line substance use disorder 
treatments that are commonly offered in Canada for people seeking help reducing or abstaining from 
substance use (section 4.2  Ensuring Access to Substance Use Disorder Treatment on page 44), 
and [2] risk mitigation strategies involving provision of replacement pharmacotherapy or managed 
alcohol for those who decline treatment or for whom conventional treatments have not been effective 
(section 4.3 Risk Mitigation Strategies to Reduce Harms Associated with Ongoing Drug and Alcohol 
Use on page 47). These risk mitigation strategies have developed in response to the combined 
health risks of the overdose epidemic and COVID-19. They are not considered substance use disorder 
treatment but rather are intended to support people with substance use disorders to self-isolate or 
social distance and avoid health risks of withdrawal, overdose or other harms related to drug use. 
Readers should note that the sections below are intended to provide general information to a wide 
variety of clinical and non-clinical staff working to support people who use substances in diverse 
shelter settings during the COVID-19 pandemic. Ability to connect residents to various substance 
use disorder treatment options and risk mitigation strategies described herein will vary according 
to the setting, the degree to which operators and residents have access to various health care 
professionals (including medical doctors or nurse practitioners who can prescribe medications when 
indicated (134,135)), and the availability of external resources to which residents can be effectively 
referred. Physicians and nurse practitioners working in shelter settings with limited experience in the 
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management of substance use disorders and presentations of intoxication or withdrawal, may benefit 
from identifying local resources or mentorship. In some jurisdictions expert consultation telephone 
services on the management of substance use disorders may be available.
4.1.2  Assessment
At any time during their stay at the shelter, participants might indicate a need for support with their 
substance use. If desired by the resident, shelter staff should facilitate access to healthcare providers 
who are able to assist with substance use disorder treatment, withdrawal management, or substance 
use stabilization/risk mitigation. Health care providers should assess patients’ substance use history 
and medical needs and work with each patient to determine their goals and develop an appropriate 
care plan. The following resources may be useful for health care professionals looking for more detailed 
guidance on assessing patients’ substance use, diagnosing substance use disorder, and documenting 
the appropriateness of various substance use disorder treatment or risk mitigation strategies:
• CRISM National Guideline for the Clinical Management of Opioid Use Disorder; CRISM (136)
• National Injectable Opioid Agonist Treatment for Opioid Use Disorder Clinical Guideline; 
CRISM (137)
• A Guideline for the Clinical Management of Opioid Use Disorder; British Columbia Centre on 
Substance Use and British Columbia Ministry of Health (138)
• Guidance Document on the Management of Substance Use in Acute Care (139)
• Provincial Guideline for the Clinical Management of High-Risk Drinking and Alcohol Use 
Disorder; British Columbia Centre on Substance Use, British Columbia Ministry of Health, and 
British Columbia Ministry of Mental Health and Addiction (140)
• Risk Mitigation in the Context of Dual Public Health Emergencies; British Columbia Centre on 
Substance Use (141)
• Screening & Assessment Tools; American Society of Addiction Medicine (142)
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4.2  ENSURING ACCESS TO SUBSTANCE USE 
DISORDER TREATMENT
All shelter residents should have access to evidence-based treatment for their substance use disorder(s). 
To provide treatment to shelter residents, operators will need to develop partnerships with health care 
professionals (i.e., medical doctors or nurse practitioners (134,135) who can prescribe medications 
when indicated), pharmacists, counsellors, social workers, peer support workers and other allied 
health professionals. How these partnerships look is dependent on a variety of factors, including 
shelter capacity and available community resources. Partnership options include embedding health 
care professionals within the shelter, using telehealth or other virtual care models, and partnering 
with nearby primary care practices, opioid agonist treatment clinics, or addiction medicine clinics. 
The partnership model chosen will influence which treatments can be initiated and maintained on 
site. Whether there is access to a pharmacy will also play a role in determining which treatments 
can be offered. Regardless of the partnership model, the goal should be ongoing access to care both 
during the COVID-19 pandemic and after it ends (either with the same health care professional or via 
seamless transfer of care; see section 4.6  Ensuring Continuity of Care after a Period of Isolation and 
Once the Immediate Threat of COVID‑19 Subsides on page 53 for more information).
When assessing the most appropriate option for a patient, health care professionals should take into 
account which medications will be covered by the public drug benefit plans (see (143) for details 
on provincial/territorial coverage of common medications). Individuals without medication coverage 
should be supported to obtain coverage; this may be facilitated by partnership with local social 
workers or government offices (144). Any specific storage requirements should also be considered. 
Note that Health Canada has recently introduced new regulatory measures designed to reduce 
barriers to prescribing and dispensing controlled substances during the COVID-19 pandemic. Please 
see their document Subsection 56(1) Class Exemption for Patients, Practitioners and Pharmacists 
Prescribing and Providing Controlled Substances in Canada during the Coronavirus Pandemic (144) 
for more information.
4.2.1 Treatment of Opioid Use Disorder
Healthcare professionals should work with their patients diagnosed with opioid use disorder to 
determine the most appropriate treatment option. Treatment for opioid use disorder typically 
includes opioid agonist treatment (OAT) with buprenorphine/naloxone, methadone, slow release 
oral morphine (SROM), or injectable opioid agonist treatment (iOAT) with hydromorphone or 
diacetylmorphine (where available). 
Buprenorphine/naloxone is the preferred first-line treatment approach for individuals with opioid use 
disorder when induction is feasible and there are no contraindications to its use, as it has fewer side 
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effects and important safety advantages compared to methadone. Methadone can be considered an 
alternate first-line option in cases where buprenorphine/naloxone induction would be challenging or 
according to patient preference. For individuals not benefiting from adequately-dosed buprenorphine/
naloxone or methadone, transitioning to the alternative first-line agent may be considered. In patients 
for whom first-line treatment options are ineffective, contraindicated, or refused, OAT with SROM 
may be considered. Kadian®, a 24 hour long acting morphine formulation, is the only product studied 
for SROM. [excerpts from the CRISM National Guideline for the Clinical Management of Opioid Use 
Disorder (136)]
For patients with treatment refractory opioid use disorder and ongoing illegal injection opioid 
use, iOAT with diacetylmorphine or hydromorphone may be appropriate treatment options where 
available. [see CRISM’s Injectable Opioid Agonist Treatment for Opioid Use Disorder National Clinical 
Guideline (137)]
For some treatment options (e.g., methadone), the stabilization period can be long. If the patient is 
isolated during the stabilization period, they may still require management of withdrawal in addition 
to their OAT. This may include provision of other prescribed opioids; see section 4.3.1  Ongoing Opioid 
Use on page 48 for more information.
Operators and health care professionals providing treatment for opioid use disorder may find the 
following resources useful:
• CRISM National Guideline for the Clinical Management of Opioid Use Disorder; CRISM (136)
• National Injectable Opioid Agonist Treatment for Opioid Use Disorder Clinical Guideline; 
CRISM (137)
• Risk Mitigation in the Context of Dual Public Health Emergencies; British Columbia Centre on 
Substance Use (141)
• Toolkit for Substance Use and Addictions Program Applicants: Stream 2 - Increasing Access to 
Pharmaceutical-Grade Medications; Health Canada (145) 
• Buprenorphine/Naloxone Microdosing: The Bernese Method: A Brief Summary for Primary 
Care Clinicians (146)
• COVID-19 Opioid Agonist Treatment Guidance; CAMH, META:PHI, and OMA (147)
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4.2.2 Treatment of Stimulant Use Disorder
There are currently no approved pharmacotherapy options for the treatment of stimulant use disorder; 
guidance on risk mitigation prescribing is provided below (see section 4.3.2 Ongoing Stimulant Use 
on page 49). Stimulant intoxication or withdrawal should be managed symptomatically (prescribing 
medications to address specific symptoms like agitation). Where possible, effective psychosocial 
treatments for stimulant use disorder should be offered, including contingency management programs 
(148–150).
4.2.3 Treatment of Benzodiazepine Use Disorder
Abrupt discontinuation of legal or illegal benzodiazepines could lead to benzodiazepine withdrawal, 
which can constitute a medical emergency and requires urgent treatment using symptom-triggered 
administration of benzodiazepines. Benzodiazepine use disorder can be managed through gradual 
benzodiazepine tapering or a period of benzodiazepine maintenance therapy (129). Since maintenance 
therapy is generally felt to increase harm (e.g. risk of fatal overdose, falls, worsening of mental health 
symptoms), an approach to maintenance may include a period of support and stabilization with 
regularly dispensing slow-onset, long-acting benzodiazepines to allow for a case-by-case assessment 
of risks and benefits (129,151,152). Health care professionals should attempt to ascertain the 
patient’s current dose, although this may be challenging due to the counterfeit products available on 
the illegal market. To account for the variability in actual dosing, health care professionals should start 
patients on a reduced dose with supplemental doses available to determine the effective dose (141). 
If patients are also using opioids or if there is concurrent alcohol use, close monitoring is required as 
benzodiazepines particularly increase the risk of respiratory depression and overdose when co-used 
with these substances (141). 
4.2.4 Treatment of Alcohol Use Disorder
Severe alcohol withdrawal is a life-threatening medical condition that may require urgent management 
to prevent complications such as cardiac arrhythmias, seizures, and delirium. Prevention of severe 
withdrawal requires regular (e.g. initially hourly) symptom assessment; if this is not feasible within 
the shelter, the patient should be transferred to acute care. Withdrawal typically presents within 
6-24 hours after a person’s last drink and can be present when alcohol levels are still elevated. 
Benzodiazepines are the standard of care for patients at risk of severe withdrawal and the Prediction 
of Alcohol Withdrawal Severity Scale (PAWSS) (153) can reliably be used to differentiate patients at 
high or low risk of severe withdrawal. Even once alcohol withdrawal has been appropriately treated 
and resolved, cravings to drink and relapse routinely occur. Medications such as naltrexone and 
acamprosate have been found to assist those with alcohol use disorder to reduce intake, support 
abstinence, and delay time to first relapse. Examples of first line medications include naltrexone and 
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acamprosate, and second line medications include gabapentin, baclofen, and valproic acid (154). 
Naltrexone should not be prescribed to patients with severe alcoholic hepatitis or decompensated 
cirrhosis, or who take opioids (including both prescribed and illegal opioids). Acamprosate is 
recommended for patients who have a treatment goal of abstinence, and is contingent on sufficient 
renal function and availability (as it is often on shortage). Neither naltrexone nor acamprosate are 
contraindicated if the patient resumes drinking (139).
4.2.5 Treatment of Tobacco Use Disorder
Many people staying at shelters consume tobacco on a daily basis, and will require nicotine replacement 
therapy (NRT)  to avoid withdrawal if wishing to abstain from tobacco use. There is a low risk of 
adverse effects with NRT. NRT in the form of gum, lozenges, or transdermal patches can be obtained 
without a prescription in some provinces, and a stock of each of these NRT options can be stocked 
on site. External funding sources may be available to aid with the cost (155); collaborating with the 
patient’s pharmacist can help to clarify what products will be covered. The type of NRT dispensed may 
depend on availability, funding, and patient preference. Patients should be encouraged to shift to NRT 
as a way of reducing vulnerability to severe outcomes associated with COVID-19, which is primarily a 
respiratory illness.
4.2.6 Treatment of Cannabis Use Disorder
Although research into pharmacological options to support individuals experiencing cannabis 
withdrawal is ongoing (156,157), these options do not have a strong evidence base as of yet. First line 
treatment for cannabis use disorder includes psychosocial treatments such as cognitive-behavioral 
therapy (CBT), motivational enhancement therapy (MET), or contingency management (158) 
if available in a shelter setting. When indicated, health care providers might consider authorizing 
cannabis for patients who qualify for medical cannabis though costs may be a barrier to access (156).
4.3 RISK MITIGATION STRATEGIES TO REDUCE 
HARMS ASSOCIATED WITH ONGOING DRUG AND 
ALCOHOL USE
Not all patients will accept or stabilize on evidence-based treatment options for their substance 
use disorders. In these cases, steps should be taken to minimize the harms associated with ongoing 
procurement and use of substances from the illegal drug market. As described above, if COVID-19 
positive patients leave shelters or isolation settings to procure and use substances, it puts themselves 
and others at risk. When evidence-based treatment options are not effective or are declined, health 
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care professionals should consider providing access to replacement medications for withdrawal and 
craving management. When prescribing replacement medications for the prevention of withdrawal, 
health care professionals should document their assessment and justification of medication choice, 
including that evidence-based, approved treatment options were ineffective or declined by the 
patient. 
Ideally, patients would be encouraged to consume medications orally, as oral ingestion is generally 
associated with the least potential harm. If this is not possible, patients would ideally be supported in 
consuming the prescribed substances through their preferred route of administration (i.e., intranasal, 
injection, inhalation). Witnessed dosing of prescribed substances may be required by regulators in 
some jurisdictions, although not all jurisdictions require witnessed dosing in the context of COVID-19 
risk mitigation (e.g., British Columbia, (141)) and some jurisdictions have not announced policies on 
this. Shelter operators could implement a designated area with consumption spaces that maintain 
physical distancing protocols and are compliant with infection prevention and control precautions, is 
monitored by staff trained in overdose response and harm reduction principles, and provides sterile 
drug consumption equipment to each patient. Note that if patients are only consuming substances 
prescribed to them, a federal exemption under section 56.1 of the Controlled Drugs and Substances 
Act is not required. Alternatively, the provision of pharmacotherapy could be integrated into an 
on-site or an external proximal supervised consumption service, which will comply with the required 
criteria for safer drug consumption. Depending on the medication, formulation, and jurisdiction, daily-
dispensing of unobserved doses to shelter residents may also be feasible. British Columbia Centre for 
Substance Use’ Risk Mitigation in the Context of Dual Public Health Emergencies provides detailed 
guidance on recommended prescribing practices (141).
4.3.1  Ongoing Opioid Use
If a patient is using illegal opioids in addition to their OAT or declines OAT, prescribe according to 
current use and use patient preference and clinical judgment to select appropriate medications and 
dosage. Dose and medication should be decided on collaboratively with each individual, via a shared 
decision-making process. Important considerations include: OAT co-prescription, amount and pattern 
of substance use (i.e., daily or binge), ongoing use of alcohol and/or other substances, and vulnerability 
to overdose and COVID-19 infection. Patients should be advised that injection of controlled release 
opioid formulations has been associated with an increased risk of serious bacterial infections including 
endocarditis (159–161). Injectable formulations or immediate release tablets could be considered for 
people who indicate a preference for injecting, although each option carries its own risk. The dose 
can be adjusted over time, with a goal of the person being comfortable and not needing to access the 
illegal drug market. [excerpts from Risk Mitigation in the Context of Dual Public Health Emergencies; 
see this document for detailed guidance on prescribing practices (141)]
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4.3.2 Ongoing Stimulant Use
The generally good safety profile of prescribed stimulants suggests that replacement therapy with 
psychostimulants could be a reasonable clinical decision in these extraordinary circumstances 
though the potential risks of exacerbating mental health challenges (e.g. agitation, psychosis) must 
be balanced with potential benefits. The available pharmacotherapy options for stimulants include 
dextroamphetamine (Dexedrine®) and methylphenidate (Ritalin®) [excerpts from Risk Mitigation in 
the Context of Dual Public Health Emergencies; see this document for detailed guidance on prescribing 
practices (141)].
4.3.3 Ongoing Alcohol Use 
Managed alcohol programs (MAPs) are a promising option for supporting shelter residents whose 
pattern of alcohol consumption may place them at increased risk of harm during COVID-19. MAPs 
provide measured quantities of beverage alcohol to people with alcohol use disorder, and are 
offered in many settings in Canada (162). Eligible participants should be assessed for the amount and 
frequency of alcohol required, which will depend on individual needs based on established drinking 
patterns to reduce harms and reduce/prevent withdrawal symptoms. The Canadian Institute for 
Substance Use Research provides a conversion tool to identify the standard drinks or volume required 
for the participant based on their typical alcohol consumption (163). While administration times 
may vary by shelter, participants should be offered alcohol after waking and prior to sleeping at a 
minimum. The patient typically signs a participation agreement document, which should clearly state 
the expectations of the patient while in the MAP (e.g., let the staff know if the dosage or frequency is 
inadequate rather than seeking out other sources of alcohol, no violence or aggression towards other 
people in the shelter, etc.) as well as outline their individualized dosing plan. The agreement can be 
modified and re-signed as necessary.
Depending on the type of shelter setting, staff could create a centralized alcohol consumption 
space only for MAP participants or provide distributed delivery of alcohol to shelter residents. For 
centralized areas, the space needs to be large enough that physical distancing is maintained, which 
can be further supported by staggering administration times if appropriate PPE is available. Other 
MAP models are distributed in that participants may consume alcohol in their room; this may include 
a daily delivery of a preset amount of alcohol allowing the participant to determine the timing of their 
own consumption. Such a model may only be possible in shelter settings where participants have their 
own room or other physical space. Prior to administering a dose, staff should assess the participant’s 
level of intoxication. If the participant is walking and standing unaided but has slight impairment to 
speech and cognition, consider administering the dose. However, if the participant has gross motor 
skill impairment and experiences challenges moving and communicating, defer the dose to the 
next administration time. Alcohol should be administered in disposable cups to eliminate the risk of 
PAGE 50  |   Supporting people who use substances in shelter settings during the COVID‑19 pandemic |  NATIONAL RAPID GUIDANCE
COVID-19 transmission. Details regarding each administration episode should be recorded. Education 
on safer drinking strategies and self-management of alcohol consumption should be provided. For 
more information on MAPs, please see The Canadian Managed Alcohol Program Study.
While a formal MAP is the ideal standard for supporting people with alcohol use disorder or high-
risk patterns of alcohol consumption, it may not be feasible in all settings. In shelters where it is 
not possible to administer a managed alcohol program, consider providing advice on alcohol harm 
reduction to residents instead. Other potential supports include: assisting with the monitoring of 
residents’ alcohol consumption; storing residents’ own alcohol in a secure location; encouraging 
them to space out their drinks, eat before consuming alcohol and switch to lower-percentage alcohol 
products; and facilitating purchase of beverage alcohol as an alternative to non-beverage alcohol 
(e.g., hand sanitizer, mouthwash, rubbing alcohol). Disposable cups should be available so that people 
do not need to drink directly from the bottle or share bottles. Sharing cups should be avoided, and 
facilities for immediate disposal of cups after use should be provided. Staff should also be aware 
of the elevated risks associated with consuming non-beverage alcohol, such as hand sanitizer, (e.g., 
toxic ingredients and increased ethanol concentration (164)), and take measures to avoid diversion of 
larger quantities of these products given that alcohol-based hand sanitizers will be more available in 
shelter settings due to their role in COVID-19 infection prevention and control efforts.
For further information on safer consumption guidelines for alcohol, please see the following 
resources:
• Alcohol Use & COVID-19 (165)
• Alcohol and COVID-19: What you Need to Know; World Health Organization (166)
• Canada’s Low-Risk Alcohol Drinking Guidelines; Canadian Centre on Substance Use and 
Addiction (167)
• Safer Drinking Tips; Canadian Institute for Substance Use Research & Eastside Illicit Drinkers 
Group for Education (168)
• Safer Drinking Tips During COVID-19; Canadian Institute for Substance Use Research & Eastside 
Illicit Drinkers Group for Education (169)
4.3.4 Ongoing Tobacco Use 
For people who continue to use tobacco, operators should designate an outdoor location at the 
emergency shelter for tobacco consumption that allows patients to maintain appropriate physical 
distancing (this area should be separate from the designated inhalation area of any supervised 
consumption service, if possible). While tobacco consumption is legal and products are relatively easily 
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accessible in Canada, access will be limited for people staying at the emergency shelter. Therefore, 
some may require support in accessing adequate nicotine to meet their needs. Consider providing 
tobacco products to residents who are not willing to participate in NRT (or as a supplement to NRT) as 
a risk reduction measure to prevent sharing of cigarettes during the COVID-19 pandemic. To promote 
health and reduce the risk of complications from possible COVID-19 infection, encourage residents 
to switch to lower strength tobacco products or to reduce the amount of cigarettes they consume 
per day. Advise against sharing cigarettes or collecting butts. Ensure that appropriate, tamper-proof 
ashtrays are provided for safely discarding cigarette butts after they have been used. Regularly empty 
ashtrays and clean smoking areas of improperly discarded butts.
Chewing tobacco is frequently used covertly in settings where smoked tobacco products are prohibited, 
as it is inside most shelters. Advise residents on infection prevention and control measures when 
using chewing tobacco, as spitting associated with chewing tobacco poses COVID-19 transmission 
risks. Providing single use containers with secure lids for ‘spittoons’ will minimize the use of informal 
solutions, such as dishes or disposable drink containers, which may spill and contaminate the 
surrounding area. 
4.3.5 Ongoing Cannabis Use
As cannabis consumption is legal in Canada, residents who wish to smoke cannabis should have 
access to a designated outdoor location for consumption (this can be incorporated into the area for 
tobacco consumption), and those who wish to consume cannabis through other routes (e.g., edibles) 
should be permitted to do so within the shelter. For those who wish to continue smoking cannabis, 
staff may consider partnering with local programs distributing cannabis at reduced cost (170) and 
providing safer cannabis consumption advice based on the Lower Risk Cannabis Use Guidelines, 
such as consuming via routes other than smoking, not smoking synthetic cannabinoids and avoiding 
inhaling deeply or holding one's breath (171), as the risk of harm from cannabis consumption is 
generally lower than that of tobacco, alcohol, and other psychoactive drugs (172). Sharing joints or 
other consumption equipment (e.g., bongs, vape pens, etc.) or collecting butts (roaches) should be 
discouraged. Appropriate, tamper-proof ashtrays should be available for joint disposal and regularly 
emptied. The smoking area should be frequently cleaned of improperly discarded debris.
4.4 ADDITIONAL CONSIDERATIONS FOR HEALTH 
CARE PROFESSIONALS
All prescriptions should consider the need for physical distancing and/or self-isolation requirements, 
and - while balancing risks of diversion to vulnerable populations - should be of long enough duration 
to facilitate compliance with these goals wherever possible. 
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There are multiple possible avenues for patients to receive their prescribed medications:
• Community pharmacies could deliver day-ahead or day-of daily dispensed medications to the 
shelter. The prescriber should indicate on the prescription that medications can be delivered to 
the patient at the shelter. Alternatively, for patients in isolation, the medication may be released to 
an authorized individual who agrees to ensure delivery to the patient (173).
• A dedicated pharmacy space could be set up on site where pharmacy staff could dispense 
medications, support witnessed ingestion of required therapies, and prescribe and administer 
maintenance medications (e.g., long acting antipsychotics, contraception). The pharmacy could 
also have essential medications on site (e.g., antibiotics). This would require appropriate staffing, 
PPE, and adequate secure storage within the shelter. 
• For patients who have access to a secure storage space, several days of medication may be 
dispensed at a time. However, daily dispensation may be preferred by some patients for certain 
therapies.
The following resources provide further details on considerations for prescribing and accessing 
controlled substances in Canada:
• Frequently Asked Questions: Access to Controlled Substances; Health Canada (135)
• Process for Establishing a Safer Supply Program in Canada; Health Canada (134)
• Relevant Exemptions to the Controlled Drugs and Substances Act; Health Canada (174)
4.5 PSYCHOSOCIAL SUPPORTS FOR PEOPLE USING 
SUBSTANCES, ACCESSING TREATMENT OR IN 
RECOVERY
Psychosocial treatment interventions and supports should be routinely offered alone or in conjunction 
with pharmacological treatment but should not be viewed as a mandatory requirement for accessing 
medications. Research evidence suggests that in uncomplicated patient populations, the addition of 
structured psychosocial treatment interventions as adjuncts to opioid agonist treatment does not 
improve treatment outcomes compared to standard medical management (i.e., general support and 
unstructured counselling in clinical encounters), which is traditionally provided as standard of care for 
treatment of substance use disorder. However, this does not suggest that pharmacotherapy should be 
offered in isolation, but rather that medical management includes ongoing assessment, monitoring, 
and support for all aspects of physical, emotional, mental, and spiritual health, as these remain 
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equally important components of treating substance use disorders; addressing these needs should 
be considered the standard of care. Evidence-based psychosocial supports focused on individual 
circumstances (e.g., employment, addiction counselling) and other survival needs (e.g., social 
assistance, housing, disability supports) may also be helpful in supporting recovery from substance 
use disorder. [excerpts from CRISM National Guideline for the Clinical Management of Opioid Use 
Disorder (137); see (154) for more information on psychosocial supports for alcohol use disorder].
People seeking to reduce their use of alcohol and drugs or work towards other self-determined goals 
should also be referred to available inpatient or outpatient treatment programs, peer support groups 
(contact Alcoholics Anonymous, SMART Recovery, or Canadian Association of People who Use Drugs 
to find out information about local groups), and other recovery supports when requested, depending 
on local availability. Where indicated, other healthcare should be provided, or a referral to appropriate 
services made. 
Entertainment options for shelter residents who use substances and those attempting to abstain from 
drug or alcohol use could help distract from potential boredom, particularly for those in isolation. This 
could include access to loaner cell phones, tablets, music devices; art supplies, and reading materials. 
These supplies must meet infection prevention and control guidelines, and must be either disposable 
or be able to be thoroughly sanitized in between uses. Where possible, to avoid risk of relapse, shelters 
may wish to designate certain areas for individuals pursuing abstinence and those in recovery that are 
separate from individuals who remain active in their drug or alcohol use.
4.6  ENSURING CONTINUITY OF CARE AFTER A 
PERIOD OF ISOLATION AND ONCE THE IMMEDIATE 
THREAT OF COVID‑19 SUBSIDES
It is important that a plan for continuing to support shelter residents who use substances be developed 
and implemented post-pandemic. Additionally, proper transition of care into the community after 
medical isolation or discharge from a temporary shelter is vital to ensuring positive outcomes and 
ultimately reducing homelessness. This includes seeking longer term housing options and robust 
healthcare access. When residents are discharged from shelter settings, community clinicians (if a 
transfer of medical care is required) should be provided with relevant documents to ensure continuity 
of therapy and management plans that include follow up appointments, medications administered 
while in the shelter, and changes in management (including its rationale) that are to continue once a 
patient completes medical isolation or is discharged from a temporary shelter. Residents should be 
discharged with a concrete plan for obtaining safe, appropriate housing and referred to relevant harm 
reduction, treatment, and recovery supports in the community. 
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Health care professionals caring for residents of medical isolation shelters should consider 
communicating with the patient’s regular community providers, as the community provider can 
provide background history and valuable input into discharge planning. If possible and appropriate, 
consider facilitating virtual care options so that people can remain attached to any regular health 
care providers. This is optimal for ensuring continuity of care. Community providers can also convey 
what goals have been set when the patient was in the community and support the medical team in 
furthering these goals while in the shelter. Inclusion of the community provider can also maximize the 
efficient use of resources. 
The following elements should be considered when preparing for the patient’s discharge from medical 
isolation or a temporary shelter and return to the care of a community provider:
• Ensure the patient has a community provider.
• Consider providing the patient with documentation of time spent in the shelter and illness 
status in case proof of illness resolution is required to access community resources or return 
to prior housing.  
• Ensure safe housing/location for discharge.
• For those on managed alcohol, refer to a community or housing-based managed alcohol 
programs, or otherwise ensure the patient has ability to maintain access to alcohol 
post-discharge.
• Ensure medication coverage is in place for all prescriptions.
• Ensure community pharmacy has prescribed medications available.
• Ensure prescriptions are sent to the community pharmacy for any ongoing medications - 
prescriptions should continue until the next follow up date and should not end on a Friday, 
Saturday, Sunday or statutory holiday. Communicate the following items to the community 
pharmacist:
 - Dose and date/time of last dose of medication administered at the shelter.
 - Who will be taking over prescribing, and date and time of next appointment.
 - Who to notify of any missed doses of medication.
 - When to hold doses.
 - Specific instructions on how to handle missed doses (if appropriate).
• Ensure primary care or other specialist appointment is arranged for ongoing prescribing.
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• Ensure discharge prescription is sufficient in duration to prevent withdrawal while the patient 
is transitioning to community supports.
• Ensure the patient has a take home naloxone kit, and other harm reduction supplies, as needed.
• All follow up plans provided verbally and in writing to the patient and any support people as 
requested by the patient.
[excerpts from the Guidance Document on the Management of Substance Use in Acute Care (139)].
4.7 REPORTING AND EVALUATION
Funding and regulatory bodies may require sites or health care professionals providing substance use 
disorder treatment or replacement pharmacotherapy to report on or evaluate the provision of care in 
support of people who use substances in shelter settings. Data collection should not impede service 
delivery, particularly in the context of an urgent pandemic-related response. Where possible, operators 
may still find value in evaluation activities to explore whether the provision of pharmacotherapy in 
the shelter enabled adherence to public health orders or guidance, to assess patient satisfaction with 
the care received, to identify opportunities for improvement, and to support the expansion of this 
service to other emergency shelter settings.
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5.0 Further Reading and Resources
• A Treatment Improvement Protocol: Trauma-Informed Care In Behavioral Health Services; 
Substance Abuse and Mental Health Services Administration (175)
• Challenges in Maintaining Treatment Services for People who use Drugs during the COVID-19 
Pandemic; Harm Reduction Journal (176)
• COVID-19 Guidance: Consumption and Treatment Services (CTS) Sites; Ontario Ministry of 
Health (88)
• COVID-19: How to Include Marginalized and Vulnerable People in Risk Communication and 
Community Engagement; The Regional Risk Communication and Community Engagement 
Working Group (177)
• COVID-19: Information for Opioid Agonist Treatment Prescribers and Pharmacists; British 
Columbia Centre on Substance Use (178)
• EMCDDA Update on the Implications of COVID-19 for People who use Drugs (PWUD) and Drug 
Service Providers; European Monitoring Centre for Drugs and Drug Addiction (179)
• Housing Services: COVID-19 Guidance for Homelessness Service Providers; Region of Peel (87)
• Interim Guidance: Scaling-Up COVID-19 Outbreak Readiness and Response Operations in 
Humanitarian Situations Including Camps and Camp-Like Settings; Inter-Agency Standing 
Committee Secretariat (180)
• Safe Supply and Harm Reduction During COVID-19; Homeless Hub (181)
• Suggestions about Treatment, Care and Rehabilitation of People with Drug Use Disorder in the 
Context of the COVID-19 Pandemic; United Nations Office on Drugs and Crime (182)
• Toolkit for Substance Use and Addictions Program Applicants: Stream 2 - Increasing Access to 
Pharmaceutical-Grade Medications; Health Canada (145)
• Trauma Informed Practice Guide; BC Provincial Mental Health and Substance Use Planning 
Council (183)
• VCH Overdose Response in Overdose Prevention Sites and Supervised Consumption Sites for 
COVID-19; Vancouver Coastal Health (96)
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Appendix 1: Example Form for 
Supervised Consumption Service 
Data Collection 
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Appendix 2: Online Substance Use 
Resources Listing
Below is a list of online resources on substance use. Please note that this is not an exhaustive list of 
resources.
Clinical Support Resources for Patients and Healthcare 
Providers
Anxiety Canada’s free MindShift™ CBT app 
This app focuses on assisting in the management of anxiety using scientifically proven strategies (free 
for iOS and Android devices) 
British Columbia Centre on Substance Use: COVID‑19
Canadian Addiction Counsellors Certification Federation
Virtual addiction counselling
CATIE – Canada’s source for HIV and hepatitis C information
College of Physicians and Surgeons of Newfoundland and Labrador ‑ Opioid Agonist Treatment 
(OAT) Guidance during COVID‑19
Community Addictions Peers Support Association (CAPSA) and Breaking Free Online
In response to COVID-19 and the increased risks for those with substance use disorders, the Community 
Addictions Peers Support Association (CAPSA) has partnered with Breaking Free Online to provide 
free access to Canadians (service code CAPSA2020)
Draft Emergency Carry Agreement 
Nova Scotia Department of Health and Wellness: Points to Guide Clinical Decision for OAT Prescribers
Nova Scotia Health Authority (NSHA) Standard Operating Procedures for Opioid Use Disorder 
Treatment (OUDT) Programs
Documents included: Overview and Infection Control Practices SOP, New Admissions and Transfers 
SOP, Ongoing Client Being Prescribed Methadone SOP, and Clients in Self-Isolation or Quarantine SOP.
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Providence Health Care Nursing Practice Standard Dispensing Injectable Opioid Agonist Therapy to 
Client With or at Risk of COVID‑19
SMART Recovery Program 
This website includes message boards, chat rooms, online meetings, and an online library of recovery 
resources
Take Home Naloxone
Free online naloxone training 
Toward the Heart
Free online naloxone training
Harm Reduction Resources
Canadian Association of People Who Use Drugs (CAPUD) 
Canadian Drug Policy Coalition: COVID‑19 Harm Reduction Resources
International Network of People Who Used Drugs: COVID‑19 Crisis: Harm Reduction Resources for 
People who Use Drugs
Mental Health and Substance Use Resources 
Centre for Addiction and Mental Health (CAMH): Mental Health and the COVID‑19 Pandemic
Narcotics Anonymous
Taking Care of Your Mental Health (COVID‑19)
Wellness Together Canada: Mental Health and Substance Use Support
Indigenous Communities
Assembly of First Nations: COVID‑19
First Nations Health Managers Association: COVID‑19 Resources and Announcement
Up-to-date information on COVID-19
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First Peoples Wellness Circle: COVID‑19 Resources page
Provides printable Information Sheets for Mental Wellness for Community; Parents and Children; 
Elders and Seniors; and Health Professionals
Thunderbird Partnership Foundation: Harm Reduction during COVID‑19
Support Resources for Healthcare Providers
Canadian Foundation for Healthcare Improvement (CFHI)
Supports partners to accelerate the identification, spread and scale of proven healthcare innovations. 
Webinar Series: Patient Partnership in a Time of COVID-19
Health Canada Subsection 56(1) Class Exemption for Patients, Practitioners and Pharmacists 
Prescribing and Providing Controlled Substances in Canada during the Coronavirus Pandemic 
In response to the evolving health risk due to COVID-19, to maintain Canadians’ access to controlled 
substances for medical treatments (e.g., treatment of substance use disorders and chronic pain), 
while they adhere to social distancing guidance from public health officials or if they need to self-
isolate, Health Canada has issued exemptions for prescriptions of controlled substances under the 
Controlled Drugs and Substances Act (CDSA) and its Regulations.
Mental Health First Aid Canada
Resource hub which provides credible information and resources for mental health for the Healthcare 
professionals “Resources for Healthcare Sector” 
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Appendix 3: Health Canada Tool Kit
Health Canada has compiled a number of resources in an effort to provide clarity regarding the rules 
that apply for substance use disorder treatment or providing a pharmaceutical grade alternative to 
the toxic street supply in Canada, in the context of COVID-19. This includes:
• A regulatory pathways graphic;
• Frequently asked questions and answers related to the legislative and regulatory requirements 
for substance use disorder treatment/safer supply;
• A list of all relevant exemptions that have been issued under the Controlled Drugs and 
Substances Act; 
• Formulary coverage under drug plans of medications used in substance use disorder treatment 
and as pharmaceutical grade alternatives to the illegal supply; and, 
• Resources related to substance use disorder treatment and providing safer supply, both in 
general and during the COVID-19 pandemic..
https://www.dropbox.com/sh/x622qndzvmydsvm/AABi888G_As
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